DK2376480T3 - Sulfonamidderivater som bcl-2-selektive apoptoseinducerende midler til behandling af cancer og immunsygdomme - Google Patents

Sulfonamidderivater som bcl-2-selektive apoptoseinducerende midler til behandling af cancer og immunsygdomme Download PDF

Info

Publication number
DK2376480T3
DK2376480T3 DK09795606.4T DK09795606T DK2376480T3 DK 2376480 T3 DK2376480 T3 DK 2376480T3 DK 09795606 T DK09795606 T DK 09795606T DK 2376480 T3 DK2376480 T3 DK 2376480T3
Authority
DK
Denmark
Prior art keywords
methyl
sulfonyl
piperazin
yloxy
indol
Prior art date
Application number
DK09795606.4T
Other languages
English (en)
Inventor
Milan Bruncko
Hong Ding
George A Doherty
Steven W Elmore
Lisa Hasvold
Laura Hexamer
Robert A Mantei
William J Mcclellan
Chang H Park
Cheol-Min Park
Andrew M Petros
Xiaohong Song
Andrew J Souers
Gerard M Sullivan
Zhi-Fu Tao
Gary T Wang
Le Wang
Xilu Wang
Michael D Wendt
Aaron R Kunzer
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41786218&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2376480(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Inc filed Critical Abbvie Inc
Application granted granted Critical
Publication of DK2376480T3 publication Critical patent/DK2376480T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/32—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)

Claims (15)

1. Forbindelse med formel II
eller terapeutisk acceptabelt salt deraf, hvor R100 er R50, OR50, SR50, S(0)R50, S02R5°, C(0)R50, C0(0)R50, 0C(0)R50, 0C(0)0R50, NH2, NHR50, N(R50)2j C(0)NH2jC(0)NHR50, C(O)N(R50)2j C(0)NH0H, C(0)NH0R50, C(0)NHS02R50, C(0)NR55S02R50, S02NH2, S02NHR50, SO2N(R50)2j CF3,CF2CF3,C(0)H, C(0)0H, C(N)NH2j C(N)NHR50, C(N)N(R50)2i OH, (O), CN, N3, N02i CF3i CF2CF3i OCF3i OCF2CF3i F, Cl, Br eller I; n erO, 1,2 eller 3; A1 er N eller C(A2); en eller to eller tre eller hver af A2, B1, D1 og E1 er udvalgt uafhængigt blandt R1, OR1, SR1, S(0)R1, S02R1, C(0)R1, C(0)0R1, 0C(0)R1 NHC1, N(R1)2j C(0)NHR1, C(0)N(R1)2, NHC(0)R1, NHC(0)0R1, NR1C(0)NHR1, NR1C(0)N(R1)2, S02NHR1, S02N(R1)2, NHS02R1, NHS02NHR1 og N(CH3)S02N(CH3)R1, og de resterende af A2, B1, D1 og E1 er udvalgt uafhængigt blandt H, F, Cl, Br, I, CN, CF3, C(0)0H, C(0)NH2 og C(0)0R1A; Y1 er H, CN, N02, C(0)0H, F, Cl, Br, I, CF3, OCF3, CF2CF3, OCF2CF3, R17, OR17, C(0)R17, C(0)0R17, SR17, NH2, NHR17, N(R17)2 NHC(0)R17, C(0)NH2, C(0)NHR17, C(0)N(R17)2, NHS(0)R17 eller NHS02R17; R1 er R2, R3, R4 eller R5; R1A er CrCe-alkyl, C3-C6-alkenyl eller C3-C6-alkynyl; R2 er phenyl, der er ufusioneret eller fusioneret med aren, heteroaren eller R2A; R2A er cycloalkan eller heterocycloalkan; R3 er heteroaryl, der er ufusioneret eller fusioneret med benzen, heteroaren eller R3A; R3A er cycloalkan eller heterocycloalkan; R4 er cycloalkyl, cycloalkenyl, heterocycloalkyl eller heterocycloalkenyl, der hver er ufusioneret eller fusioneret med aren, heteroaren eller R4A; R4A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R5 er alkyl, alkenyl eller alkynyl, der hver er usubstitueret eller substitueret med en eller to eller tre uafhængigt udvalgte R6, R7, OR7, SR7, S(0)R7, S02R7, NHR7, N(R7)2, C(0)R7, C(0)NH2i C(0)NHR7, NHC(0)R7, NHS02R7, NHC(0)0R7, S02NH2, S02NHR7, S02N(R7)2, NHC(0)NH2, NHC(0)NHR7, NHC(0)CH(CH3)NHC(0)CH(CH3)NH2, NHC(0)CH(CH3)NHC(0)CH(CH3)NHR1, OH, (O), C(0)0H, (O), N3, CN, NH2j CF3j CF2CF3j F, Cl, Br eller I substituenter; R6 er C2-C5-spiroalkyl, der hver er usubstitueret eller substitueret med OH, (O), N3, CN, CF3, CF2CF3j F, Cl, Br, I, NH2, NH(CH3) eller N(CH3)2; R7 er R8, R9, R10 eller R11; R8 er phenyl, der er ufusioneret eller fusioneret med aren, heteroaren eller R8A; R8A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R9 er heteroaryl, der er ufusioneret eller fusioneret med aren, heteroaren eller R9A; RØA gr cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R10 er C3-C10-cycloalkyl eller C4-C10-cycloalkenyl, der hver har en eller to CH2-dele, der er usubstitueret eller substitueret med uafhængigt udvalgte O, C(O), CNOH, CNOCH3, S, S(O), S02 eller NH, og en eller to CH-dele, der er usubstitueret eller substitueret med N, og hver er disse er ufusioneret eller fusioneret med aren, heteroaren eller R10A; R10A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R11 er alkyl, alkenyl eller alkynyl, der hver er usubstitueret eller substitueret med en eller to eller tre uafhængigt udvalgte R12, OR12, NHR12, N(R12)2, C(0)NH2, C(0)NHR12, C(0)N(R12)2, OH, (O), C(0)0H, N3, CN, NH2, CF3, CF2CF3, F, Cl, Br eller I substituenter; R12 er R13, R14, R15 eller R16; R13 er phenyl, der er ufusioneret eller fusioneret med aren, heteroaren eller R13A; R13A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R14 er heteroaryl, der hver er ufusioneret eller fusioneret med aren, heteroaren eller R14A; R14A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R15 er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken, der hver er ufusioneret eller fusioneret med aren, heteroaren eller R15A; R15A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R16 er alkyl, alkenyl eller alkynyl; R17 er R18, R19, R20 eller R21; R18 er phenyl, der er ufusioneret eller fusioneret med aren, heteroaren eller R18A; R18A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R19 er heteroaryl, der er ufusioneret eller fusioneret med aren, heteroaren eller R19A; risa er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R20 er C3-Ci0-cycloalkyl eller C4-Ci0-cycloalkenyl, der hver har en eller to CH2-dele, der er usubstitueret eller substitueret med uafhængigt udvalgte O, C(O), CNOH, CNOCH3, S, S(O), S02 eller NH, og en eller to CH-dele, der er usubstitueret eller substitueret med N, og hver er disse er ufusioneret eller fusioneret med aren, heteroaren eller R20A; R20A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R21 er alkyl, alkenyl eller alkynyl, der hver er usubstitueret eller substitueret med en eller to eller tre uafhængigt udvalgte R22, OR22, NHR22, N(R22)2, C(0)NH2, C(0)NHR22, C(0)N(R22)2, OH, (O), C(0)0H, N3, CN, NH2, CF3, CF2CF3, F, Cl, Br eller I substituenter; R22 er R23, R24 eller R25; R23 er phenyl, der er ufusioneret eller fusioneret med aren, heteroaren eller R23A- r23a er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R24 er heteroaren, der er ufusioneret eller fusioneret med aren, heteroaren eller R24A; r24a er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R25 er C3-C6-cycloalkyl eller C4-C6-cycloalkenyl, der hver har en eller to CH2-dele, der er usubstitueret eller substitueret med uafhængigt udvalgte O, C(O), CNOH, CNOCH3, S, S(O), S02 eller NH, og en eller to CH-dele, der er usubstitueret eller substitueret med N, og hver er disse er ufusioneret eller fusioneret med aren, heteroaren eller R25A; R25A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R30 er cycloalkyl eller cycloalkenyl, der hver har en eller to CH2-dele, der er usubstitueret eller substitueret med uafhængigt udvalgte O, C(O), CNOH, CNOCH3, S, S(O), S02 eller NH, og en eller to CH-dele, der er usubstitueret eller substitueret med N, og hver er disse er ufusioneret eller fusioneret med aren, heteroaren eller R30A; R30A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; der hver er substitueret med F, Cl, Br, I, CH2R37, CH(R31)(R37), C(R31)(R31A)(R37), C(0)R37, OR37, SR37, S(0)R37, S02R37, NHR37 eller N(R32)R37; R31 og R31A uafhængigt er F, Cl, Br eller alkyl eller sammen er C2-C5-spiroalkyl; R32 er R33, C(0)R33 eller C(0)0R33; R33 er R34 eller R35; R34 er phenyl, der er ufusioneret eller fusioneret med aryl, heteroaryl eller R34A; R34A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R35 er alkyl, der er usubstitueret eller substitueret med R36; R36 er phenyl, der er ufusioneret eller fusioneret med aren, heteroaren eller R36A; r36a er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R37 er R38, R39 eller R40, der hver er substitueret med F, Cl, Br, I, R41, OR41, NHR41, N(R41)2, NHC(0)0R41, SR41, S(0)R41 eller S02R41; R38 er phenyl, der er ufusioneret eller fusioneret med aren, heteroaren eller R38A- r38a er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R39 er heteroaryl, der er ufusioneret eller fusioneret med aren, heteroaren eller R39A- r39a er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R40 er C3-C8-cycloalkyl eller C4-C8-cycloalkenyl, der hver har en eller to CH2-dele, der er usubstitueret eller substitueret med uafhængigt udvalgte O, C(O), CNOH, CNOCH3, S, S(O), S02 eller NH, og en eller to CH-dele, der er usubstitueret eller substitueret med N, og hver er disse er ufusioneret eller fusioneret med aren, heteroaren eller R40A; R40A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R41 er R42 R43, R44 eller R45; R42 er phenyl, der er ufusioneret eller fusioneret med aren, heteroaren eller R42A- r42a er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R43 er heteroaryl, der er ufusioneret eller fusioneret med aren, heteroaren eller R43A- r43a er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R44 er C3-C9-cycloalkyl eller C4-C7-cycloalkenyl, der hver har en eller to CH2-dele, der er usubstitueret eller substitueret med uafhængigt udvalgte O, C(O), CNOH, CNOCH3, S, S(O), S02 eller NH, og en eller to CH-dele, der er usubstitueret eller substitueret med N, og hver er disse er ufusioneret eller fusioneret med aren, heteroaren eller R44A; R44A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R45 er alkyl, alkenyl eller alkynyl, der hver er usubstitueret eller substitueret med en eller to uafhængigt udvalgte R46, OR46, NHR46, N(R46)2, C(0)NH2, C(0)NHR46, C(0)N(R46)2, OH, (O), C(0)0H, N3, CN, NH2, CF3, CF2CF3, F, Cl, Br eller I substituenter; R46 er R47, R48 eller R49; R47 er phenyl, der er ufusioneret eller fusioneret med aren, heteroaren eller R47A; r47a er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R48 er heteroaryl eller R48A; R48A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R49 er C3-C6-cycloalkyl eller C4-C6-cycloalkenyl, der hver har en eller to CH2-dele, der er usubstitueret eller substitueret med uafhængigt udvalgte O, C(O), CNOH, CNOCH3, S, S(O), S02 eller NH, og en eller to CH-dele, der er usubstitueret eller substitueret med N, og hver er disse er ufusioneret eller fusioneret med aren, heteroaren eller R49A; R49A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; hvor dele som vist ved R2, R3, R4, R6, R6C, R8, R8A, R9, R10, R13, R14, R15, R18, R19 R20, R23_ R24j R25j R26j R27j R28j R29 R30j R34j R36j R38 R39j R40j R42_ R43j R44j R47, R48 og R49 uafhængigt er usubstitueret, yderligere usubstitueret, substitueret eller yderligere substitueret med en eller to eller tre eller fire eller fem uafhængigt udvalgte R50, OR50, SR50, S(0)R5°, S02R5°, C(0)R5°, C0(0)R5°, 0C(0)R5°, 0C(0)0R5°, NH2, NHR50, N(R50)2, C(0)NH2, C(0)NHR50, C(O)N(R50)2, C(0)NH0H, C(0)NH0R50, C(0)NHS02R50, C(O)NR50SO2R50, S02NH2S02NHR50, SO2N(R50)2, CF3j CF2CF3j C(0)H, C(0)0H, C(N)NH2j C(N)NHR50, C(N)N(R50)2, OH, (O), CN, N3, N02, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br eller I substituenter; R50 er R51, R52, R53 eller R54; R51 er phenyl, der er ufusioneret eller fusioneret med aren, heteroaren eller R51B- r5ib er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R52 er heteroaryl; R53 er C3-C6-cycloalkyl eller C4-C6-cycloalkenyl, der hver har en eller to CH2-dele, der er usubstitueret eller substitueret med uafhængigt udvalgte O, C(O), CNOH, CNOCH3, S, S(O), S02 eller NH, og en eller to CH-dele, der er usubstitueret eller substitueret med N, og hver er disse er ufusioneret eller fusioneret med aren, heteroaren eller R53B; hvor R53B er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R54 er alkyl, alkenyl eller alkynyl, der hver er usubstitueret eller substitueret med en eller to eller tre uafhængigt udvalgte R55, OR55, SR55, S(0)R55, S02R55, NHR55, N(R55)2, C(0)R55, C(0)NH2, C(0)NHR55, NHC(0)R55, NHS02R55, NHC(0)0R55, S02NH2, S02NHR55, S02N(R55)2, NHC(0)NH2, NHC(0)NHR55, OH, (O), C(0)0H, (O), N3, CN, NH2, CF3, OCF3, CF2CF3, OCF2CF3, F, Cl, Br eller I substituenter; R55 er alkyl, alkenyl, alkynyl, phenyl, heteroaryl eller R56; hvor alkyl, alkenyl, alkynyl er usubstitueret eller substitueret med OCH3; og R56 er C3-C8-cycloalkyl eller C4-C6-cycloalkenyl, der hver har en eller to CH2-dele, der er usubstitueret eller substitueret med uafhængigt udvalgte O, C(O), CNOH, CNOCH3, S, S(O), S02 eller NH, og en eller to CH-dele, der er usubstitueret eller substitueret med N.
2. Forbindelse med formel III
eller terapeutisk acceptabelt salt deraf, hvor R100 er R50, OR50, SR50, S(0)R50, S02R5°, C(0)R50, C0(0)R50, 0C(0)R50, 0C(0)0R50, NH2, NHR50, N(R50)2j C(0)NH2j C(0)NHR50, C(O)N(R50)2j C(0)NH0H, C(0)NH0R5°, C(0)NHS02R50, C(0)NR55S02R50, S02NH2, S02NHR50, SO2N(R50)2i CF3i CF2CF3i C(0)H, C(0)0H, C(N)NH2i C(N)NHR50, C(N)N(R50)2j OH, (O), CN, N3, N02j CF3j CF2CF3j OCF3j OCF2CF3j F, Cl, Br eller I; n erO, 1,2 eller 3; A1 er N eller C(A2); en eller to eller tre eller hver af A2, B1, D1 og E1 er udvalgt uafhængigt blandt R1, OR1, SR1, S(0)R1, S02R1, C(0)R1, C(0)0R1, 0C(0)R1, NHR1, N(R1)2, C(0)NHR1, C(0)N(R1)2, NHC(0)R1, NHC(0)0R1, NR1C(0)NHR1, NR1C(0)N(R1)2, S02NHR1, S02N(R1)2 NHS02R1, NHS02NHR1 og N(CH3)S02N(CH3)R1, og de resterende af A2, B1, D1 og E1 er udvalgt uafhængigt blandt H, F, Cl, Br, I, CN, CF3, C(0)0H, C(0)NH2 og C(0)0R1A Y1 er H, CN, N02, C(0)0H, F, Cl, Br, I, CF3, OCF3, CF2CF3, OCF2CF3, R17, OR17, C(0)R17, C(0)0R17, SR17, NH2, NHR17, N(R17)2, NHC(0)R17, C(0)NH2, C(0)NHR17, C(0)N(R17)2, NHS(0)R17 eller NHS02R17; R1 er R2, R3, R4 eller R5; R1A er Ci-C6-alkyl, C3-C6-alkenyl eller C3-C6-alkynyl; R2 er phenyl, der er ufusioneret eller fusioneret med aren, heteroaren eller R2A; R2A er cycloalkan eller heterocycloalkan; R3 er heteroaryl, der er ufusioneret eller fusioneret med benzen, heteroaren eller R3A; R3A er cycloalkan eller heterocycloalkan; R4 er cycloalkyl, cycloalkenyl, heterocycloalkyl eller heterocycloalkenyl, der hver er ufusioneret eller fusioneret med aren, heteroaren eller R4A; R4A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R5 er alkyl, alkenyl eller alkynyl, der hver er usubstitueret eller substitueret med en eller to eller tre uafhængigt udvalgte R6, R7, OR7, SR7, S(0)R7, S02R7, NHR7, N(R7)2, C(0)R7, C(0)NH2, C(0)NHR7, NHC(0)R7, NHS02R7, NHC(0)0R7, S02NH2S02NHR7, S02N(R7)2i NHC(0)NH2i NHC(0)NHR7, NHC(0)CH(CH3)NHC(0)CH(CH3)NH2, NHC(0)CH(CH3)NHC(0)CH(CH3)NHR1, OH, (O), C(0)0H, (O), N3, CN, NH2j CF3j CF2CF3j F, Cl, Br eller I substituenter; R6 er C2-C5-spiroalkyl, der hver er usubstitueret eller substitueret med OH, (O), N3, CN, CF3, CF2CF3, F, Cl, Br, I, NH2, NH(CH3) eller N(CH3)2; R7 er R8, R9, R10 eller R11; R8 er phenyl, der er ufusioneret eller fusioneret med aren, heteroaren eller R8A; R8A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R9 er heteroaryl, der er ufusioneret eller fusioneret med aren, heteroaren eller R9A; R9A gr cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R10 er C3-C10-cycloalkyl eller C4-C10-cycloalkenyl, der hver har en eller to CH2-dele, der er usubstitueret eller substitueret med uafhængigt udvalgte O, C(O), CNOH, CNOCH3, S, S(O), S02 eller NH, og en eller to CH-dele, der er usubstitueret eller substitueret med N, og hver er disse er ufusioneret eller fusioneret med aren, heteroaren eller R10A; R10A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R11 er alkyl, alkenyl eller alkynyl, der hver er usubstitueret eller substitueret med en eller to eller tre uafhængigt udvalgte R12, OR12, NHR12, N(R12)2, C(0)NH2, C(0)NHR12, C(0)N(R12)2, OH, (O), C(0)0H, N3, CN, NH2, CF3, CF2CF3, F, Cl, Br eller I substituenter; R12 er R13, R14, R15 eller R16; R13 er phenyl, der er ufusioneret eller fusioneret med aren, heteroaren eller R13A; R13A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R14 er heteroaryl, der hver er ufusioneret eller fusioneret med aren, heteroaren eller R14A; R14A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R15 er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken, der hver er ufusioneret eller fusioneret med aren, heteroaren eller R15A; R15A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R16 er alkyl, alkenyl eller alkynyl; R17 er R18, R19, R20 eller R21; R18 er phenyl, der er ufusioneret eller fusioneret med aren, heteroaren eller R18A; R18A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R19 er heteroaryl, der er ufusioneret eller fusioneret med aren, heteroaren eller R19A; R19A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R20 er C3-C10-cycloalkyl eller C4-C10-cycloalkenyl, der hver har en eller to CH2-dele, der er usubstitueret eller substitueret med uafhængigt udvalgte O, C(O), CNOH, CNOCH3, S, S(O), S02 eller NH, og en eller to CH-dele, der er usubstitueret eller substitueret med N, og hver er disse er ufusioneret eller fusioneret med aren, heteroaren eller R20A; R20A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R21 er alkyl, alkenyl eller alkynyl, der hver er usubstitueret eller substitueret med en eller to eller tre uafhængigt udvalgte R22, OR22, NHR22, N(R22)2, C(0)NH2, C(0)NHR22, C(0)N(R22)2 OH, (O), C(0)0H, N3, CN, NH2, CF3, CF2CF3, F, Cl, Br eller I substituenter; R22 er R23, R24 eller R25; R23 er phenyl, der er ufusioneret eller fusioneret med aren, heteroaren eller R23A- r23a er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R24 er heteroaren, der er ufusioneret eller fusioneret med aren, heteroaren eller R24A- r24a er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R25 er C3-C6-cycloalkyl eller C4-C6-cycloalkenyl, der hver har en eller to CH2-dele, der er usubstitueret eller substitueret med uafhængigt udvalgte O, C(O), CNOH, CNOCH3, S, S(O), S02 eller NH, og en eller to CH-dele, der er usubstitueret eller substitueret med N, og hver er disse er ufusioneret eller fusioneret med aren, heteroaren eller R25A; R25A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R30 er cycloalkyl eller cycloalkenyl, der hver har en eller to CH2-dele, der er usubstitueret eller substitueret med uafhængigt udvalgte O, C(O), CNOH, CNOCH3, S, S(O), S02 eller NH, og en eller to CH-dele, der er usubstitueret eller substitueret med N, og hver er disse er ufusioneret eller fusioneret med aren, heteroaren eller R30A; R30A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; der hver er substitueret med F, Cl, Br, I, CH2R37, CH(R31)(R37), C(R31)(R31A)(R37), C(0)R37, OR37, SR37, S(0)R37, S02R37, NHR37 eller N(R32)R37; R31 og R31A uafhængigt er F, Cl, Br eller alkyl eller sammen er C2-C5-spiroalkyl; R32 er R33, C(0)R33 eller C(0)0R33; R33 er R34 eller R35; R34 er phenyl, der er ufusioneret eller fusioneret med aryl, heteroaryl eller R34A; R34A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R35 er alkyl, der er usubstitueret eller substitueret med R36; R36 er phenyl, der er ufusioneret eller fusioneret med aren, heteroaren eller R36A- r36a er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R37 er R38, R39 eller R40, der hver er substitueret med F, Cl, Br, I, R41, OR41, NHR41, N(R41)2, NHC(0)0R41, SR41, S(0)R41 eller S02R41; R38 er phenyl, der er ufusioneret eller fusioneret med aren, heteroaren eller R38A- r38a er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R39 er heteroaryl, der er ufusioneret eller fusioneret med aren, heteroaren eller R39A- r39a er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R40 er C3-C8-cycloalkyl eller C4-C8-cycloalkenyl, der hver har en eller to CH2-dele, der er usubstitueret eller substitueret med uafhængigt udvalgte O, C(O), CNOH, CNOCH3, S, S(O), S02 eller NH, og en eller to CH-dele, der er usubstitueret eller substitueret med N, og hver er disse er ufusioneret eller fusioneret med aren, heteroaren eller R40A; R40A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R41 er R42, R43, R44 eller R45; R42 er phenyl, der er ufusioneret eller fusioneret med aren, heteroaren eller R42A; R42A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R43 er heteroaryl, der er ufusioneret eller fusioneret med aren, heteroaren eller R43A- r43a er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R44 er C3-C9-cycloalkyl eller C4-C7-cycloalkenyl, der hver har en eller to CH2-dele, der er usubstitueret eller substitueret med uafhængigt udvalgte O, C(O), CNOH, CNOCH3, S, S(O), S02 eller NH, og en eller to CH-dele, der er usubstitueret eller substitueret med N, og hver er disse er ufusioneret eller fusioneret med aren, heteroaren eller R44A; R44A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R45 er alkyl, alkenyl eller alkynyl, der hver er usubstitueret eller substitueret med en eller to uafhængigt udvalgte R46, OR46, NHR46, N(R46)2, C(0)NH2, C(0)NHR46, C(0)N(R46)2, OH, (O), C(0)0H, N3, CN, NH2, CF3, CF2CF3, F, Cl, Br eller I substituenter; R46 er R47, R48 eller R49; R47 er phenyl, der er ufusioneret eller fusioneret med aren, heteroaren eller R47A; r47a er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R48 er heteroaryl eller R48A; R48A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R49 er C3-C6-cycloalkyl eller C4-C6-cycloalkenyl, der hver har en eller to CH2-dele, der er usubstitueret eller substitueret med uafhængigt udvalgte O, C(O), CNOH, CNOCH3, S, S(O), S02 eller NH, og en eller to CH-dele, der er usubstitueret eller substitueret med N, og hver er disse er ufusioneret eller fusioneret med aren, heteroaren eller R49A; R49A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; hvor dele som vist ved R2, R3, R4, R6, R6C, R8, R8A, R9, R10, R13, R14, R15, R18, R19, R20, R23, R24, R25, R26, R27, R28, R29, R30, R34, R36, R38, R39, R40, R42, R43, R44, R47, R48, R19, R20, R23, R24, R25, R26, R27, R28, R29, R30, R34, R36, R38, R39, R40, R42, R43, R44, R47, R48 og R49 uafhængigt er usubstitueret, yderligere usubstitueret, substitueret eller yderligere substitueret med en eller to eller tre eller fire eller fem uafhængigt udvalgte R50, OR50, SR50, S(0)R5°, S02R5°, C(0)R5°, C0(0)R5°, 0C(0)R5°, 0C(0)0R5°, NH2, NHR50, N(R50)2, C(0)NH2, C(0)NHR50, C(O)N(R50)2, C(0)NH0H, C(0)NH0R50, C(0)NHS02R50, C(O)NR50SO2R50, S02NH2, S02NHR50, SO2N(R50)2j CF3j CF2CF3j C(0)H, C(0)0H, C(N)NH2, C(N)NHR50, C(N)N(R50)2j OH, (O), CN, n3, no2, cf3, CF2CF3j OCF3j OCF2CF3j F, Cl, Br eller I substituenter; R50 er R51, R52, R53 eller R54; R51 er phenyl, der er ufusioneret eller fusioneret med aren, heteroaren eller R51B; R51B er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R52 er heteroaryl; R53 er C3-C6-cycloalkyl eller C4-C6-cycloalkenyl, der hver har en eller to CH2-dele, der er usubstitueret eller substitueret med uafhængigt udvalgte O, C(O), CNOH, CNOCH3, S, S(O), S02 eller NH, og en eller to CH-dele, der er usubstitueret eller substitueret med N, og hver er disse er ufusioneret eller fusioneret med aren, heteroaren eller R53B; hvor R53B er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R54 er alkyl, alkenyl eller alkynyl, der hver er usubstitueret eller substitueret med en eller to eller tre uafhængigt udvalgte R55, OR55, SR55, S(0)R55, S02R55, NHR55, N(R55)2, C(0)R55, C(0)NH2, C(0)NHR55, NHC(0)R55, NHS02R55, NHC(0)0R55 S02NH2, S02NHR55, S02N(R55)2, NHC(0)NH2, NHC(0)NHR55, OH, (O), C(0)0H, (O), N3, CN, NH2, CF3, OCF3, CF2CF3, OCF2CF3, F, Cl, Br eller I substituenter; R55 er alkyl, alkenyl, alkynyl, phenyl, heteroaryl eller R56; hvor alkyl, alkenyl, alkynyl er usubstitueret eller substitueret med OCH3; og R56 er C3-C8-cycloalkyl eller C4-C6-cycloalkenyl, der hver har en eller to CH2-dele, der er usubstitueret eller substitueret med uafhængigt udvalgte O, C(O), CNOH, CNOCH3, S, S(O), S02 eller NH, og en eller to CH-dele, der er usubstitueret eller substitueret med N.
3. Forbindelse med formel IV
eller terapeutisk acceptabelt salt deraf, hvor R100 er R50, OR50, SR50, S(0)R50, S02R5°, C(0)R50, C0(0)R50, 0C(0)R50, 0C(0)0R50, NH2, NHR50, N(R50)2j C(0)NH2j C(0)NHR50, C(O)N(R50)2j C(0)NH0H, C(0)NH0R50, C(0)NHS02R50, C(0)NR55S02R50, S02NH2, S02NHR50, SO2N(R50)2j CF3j CF2CF3j C(0)H, C(0)0H, C(N)NH2j C(N)NHR50, C(N)N(R50)2j OH, (O), CN, N3, N02j CF3j CF2CF3j OCF3j OCF2CF3j F, Cl, Br eller I; n erO, 1,2 eller 3; A1 er N eller 0(Α2}; en eller to eller tre eller hver af A2, B1, D1 og E1 er udvalgt uafhængigt blandt R1, OR1, SR1, S(0)R1, S02R1, C(0)R1, C(0)0R1, 0C(0)R1, NHR1, N(R1)2, C(0)NHR1, C(0)N(R1)2, NHC(0)R1, NHC(0)0R1, NR1C(0)NHR1, NR1C(0)N(R1)2, S02NHR1, S02N(R1)2, NHS02R1, NHS02NHR1 og N(CH3)S02N(CH3)R1, og de resterende af A2, B1, D1 og E1 er udvalgt uafhængigt blandt H, F, Cl, Br, I, CN, CF3, C(0)0H, C(0)NH2 og C(0)0R1A; Y1 er H, CN, N02, C(0)0H, F, Cl, Br, I, CF3, OCF3, CF2CF3, OCF2CF3, R17, OR17, C(0)R17, C(0)0R17, SR17, NH2, NHR17, N(R17)2, NHC(0)R17, C(0)NH2, C(0)NHR17, C(0)N(R17)2, NHS(0)R17 eller NHS02R17; R1 er R2, R3, R4 eller R5; R1A er CrCe-alkyl, C3-C6-alkenyl eller C3-C6-alkynyl; R2 er phenyl, der er ufusioneret eller fusioneret med aren, heteroaren eller R2A; R2A er cycloalkan eller heterocycloalkan; R3 er heteroaryl, der er ufusioneret eller fusioneret med benzen, heteroaren eller R3A; R3A er cycloalkan eller heterocycloalkan; R4 er cycloalkyl, cycloalkenyl, heterocycloalkyl eller heterocycloalkenyl, der hver er ufusioneret eller fusioneret med aren, heteroaren eller R4A; R4A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R5 er alkyl, alkenyl eller alkynyl, der hver er usubstitueret eller substitueret med en eller to eller tre uafhængigt udvalgte R6, R7, OR7, SR7, S(0)R7, S02R7, NHR7, N(R7)2, C(0)R7, C(0)NH2, C(0)NHR7, NHC(0)R7, NHS02R7, NHC(0)0R7, S02NH2, S02NHR7, S02N(R7)2, NHC(0)NH2, NHC(0)NHR7, NHC(0)CH(CH3)NHC(0)CH(CH3)NH2, NHC(0)CH(CH3)NHC(0)CH(CH3)NHR1, OH, (O), C(0)0H, (O), N3> CN, NH2j CF3j CF2CF3j F, Cl, Br eller I substituenter; R6 er C2-C5-spiroalkyl, der hver er usubstitueret eller substitueret med OH, (O), N3, CN, CF3, CF2CF3, F, Cl, Br, I, NH2, NH(CH3) eller N(CH3)2; R7 er R8, R9, R10 eller R11; R8 er phenyl, der er ufusioneret eller fusioneret med aren, heteroaren eller R8A; R8A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R9 er heteroaryl, der er ufusioneret eller fusioneret med aren, heteroaren eller R9A; R9A gr cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R10 er C3-Ci0-cycloalkyl eller C4-Ci0-cycloalkenyl, der hver har en eller to CH2-dele, der er usubstitueret eller substitueret med uafhængigt udvalgte O, C(O), CNOH, CNOCH3, S, S(O), S02 eller NH, og en eller to CH-dele, der er usubstitueret eller substitueret med N, og hver er disse er ufusioneret eller fusioneret med aren, heteroaren eller R10A; R10A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R11 er alkyl, alkenyl eller alkynyl, der hver er usubstitueret eller substitueret med en eller to eller tre uafhængigt udvalgte R12, OR12, NHR12, N(R12)2, C(0)NH2, C(0)NHR12, C(0)N(R12)2, OH, (O), C(0)0H, N3, CN, NH2, CF3, CF2CF3, F, Cl, Br eller I substituenter; R12 er R13, R14, R15 eller R16; R13 er phenyl, der er ufusioneret eller fusioneret med aren, heteroaren eller R13A; R13A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R14 er heteroaryl, der hver er ufusioneret eller fusioneret med aren, heteroaren eller R14A; R14A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R15 er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken, der hver er ufusioneret eller fusioneret med aren, heteroaren eller R15A; R15A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R16 er alkyl, alkenyl eller alkynyl; R17 er R18, R19, R20 eller R21; R18 er phenyl, der er ufusioneret eller fusioneret med aren, heteroaren eller R18A; risa er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R19 er heteroaryl, der er ufusioneret eller fusioneret med aren, heteroaren eller R19A; R19A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R20 er C3-C10-cycloalkyl eller C4-C10-cycloalkenyl, der hver har en eller to CH2-dele, der er usubstitueret eller substitueret med uafhængigt udvalgte O, C(O), CNOH, CNOCH3, S, S(O), S02 eller NH, og en eller to CH-dele, der er usubstitueret eller substitueret med N, og hver er disse er ufusioneret eller fusioneret med aren, heteroaren eller R20A; R20A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R21 er alkyl, alkenyl eller alkynyl, der hver er usubstitueret eller substitueret med en eller to eller tre uafhængigt udvalgte R22, OR22, NHR22, N(R22)2, C(0)NH2, C(0)NHR22, C(0)N(R22)2, OH, (O), C(0)0H, N3, CN, NH2, CF3, CF2CF3, F, Cl, Br eller I substituenter; R22 er R23, R24 eller R25; R23 er phenyl, der er ufusioneret eller fusioneret med aren, heteroaren eller R23A- r23a er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R24 er heteroaren, der er ufusioneret eller fusioneret med aren, heteroaren eller R24A- r24a er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R25 er C3-C6-cycloalkyl eller C4-C6-cycloalkenyl, der hver har en eller to CH2-dele, der er usubstitueret eller substitueret med uafhængigt udvalgte O, C(O), CNOH, CNOCH3, S, S(O), S02 eller NH, og en eller to CH-dele, der er usubstitueret eller substitueret med N, og hver er disse er ufusioneret eller fusioneret med aren, heteroaren eller R25A; R25A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R30 er cycloalkyl eller cycloalkenyl, der hver har en eller to CH2-dele, der er usubstitueret eller substitueret med uafhængigt udvalgte O, C(O), CNOH, CNOCH3, S, S(O), S02 eller NH, og en eller to CH-dele, der er usubstitueret eller substitueret med N, og hver er disse er ufusioneret eller fusioneret med aren, heteroaren eller R30A; R30A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; der hver er substitueret med F, Cl, Br, I, CH2R37, CH(R31)(R37), C(R31)(R31A)(R37), C(0)R37, OR37, SR37, S(0)R37, S02R37, NHR37 eller N(R32)R37; R31 og R31A uafhængigt er F, Cl, Br eller alkyl eller sammen er C2-C5-spiroalkyl; R32 er R33, C(0)R33 eller C(0)0R33; R33 er R34 eller R35; R34 er phenyl, der er ufusioneret eller fusioneret med aryl, heteroaryl eller R34A; R34A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R35 er alkyl, der er usubstitueret eller substitueret med R36; R36 er phenyl, der er ufusioneret eller fusioneret med aren, heteroaren eller R36A; r36a er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R37 er R38, R39 eller R40, der hver er substitueret med F, Cl, Br, I, R41, OR41, NHR41, N(R41)2, NHC(0)0R41, SR41, S(0)R41 eller S02R41; R38 er phenyl, der er ufusioneret eller fusioneret med aren, heteroaren eller R38A- R38A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R39 er heteroaryl, der er ufusioneret eller fusioneret med aren, heteroaren eller R39A- r39a er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R40 er C3-C8-cycloalkyl eller C4-C8-cycloalkenyl, der hver har en eller to CH2-dele, der er usubstitueret eller substitueret med uafhængigt udvalgte O, C(O), CNOH, CNOCH3, S, S(O), S02 eller NH, og en eller to CH-dele, der er usubstitueret eller substitueret med N, og hver er disse er ufusioneret eller fusioneret med aren, heteroaren eller R40A; R40A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R41 er R42, R43, R44 eller R45; R42 er phenyl, der er ufusioneret eller fusioneret med aren, heteroaren eller R42A; R42A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R43 er heteroaryl, der er ufusioneret eller fusioneret med aren, heteroaren eller R43A- r43a er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R44 er C3-C9-cycloalkyl eller C4-C7-cycloalkenyl, der hver har en eller to CH2-dele, der er usubstitueret eller substitueret med uafhængigt udvalgte O, C(O), CNOH, CNOCH3, S, S(O), S02 eller NH, og en eller to CH-dele, der er usubstitueret eller substitueret med N, og hver er disse er ufusioneret eller fusioneret med aren, heteroaren eller R44A; R44A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R45 er alkyl, alkenyl eller alkynyl, der hver er usubstitueret eller substitueret med en eller to uafhængigt udvalgte R46, OR46, NHR46, N(R46)2, C(0)NH2, C(0)NHR46, C(0)N(R46)2, OH, (O), C(0)0H, N3, CN, NH2, CF3, CF2CF3, F, Cl, Br eller I substituenter; R46 er R47, R48 eller R49; R47 er phenyl, der er ufusioneret eller fusioneret med aren, heteroaren eller R47A- r47a er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R48 er heteroaryl eller R48A; R48A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R49 er C3-C6-cycloalkyl eller C4-C6-cycloalkenyl, der hver har en eller to CH2-dele, der er usubstitueret eller substitueret med uafhængigt udvalgte O, C(O), CNOH, CNOCH3, S, S(O), S02 eller NH, og en eller to CH-dele, der er usubstitueret eller substitueret med N, og hver er disse er ufusioneret eller fusioneret med aren, heteroaren eller R49A; R49A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; hvor dele som vist ved R2, R3, R4, R6, R6c, R8, R8A, R9, R10, R13, R14, R15, R18, R19, R20, R23, R24, R25, R26, R27, R28, R29, R30, R34, R36, R38, R39, R40, R42, R43, R44, R47, R48 og R49 uafhængigt er usubstitueret, yderligere usubstitueret, substitueret eller yderligere substitueret med en eller to eller tre eller fire eller fem uafhængigt udvalgte R50, OR50, SR50, S(0)R5°, S02R5°, C(0)R5°, C0(0)R5°, 0C(0)R5°, 0C(0)0R5°, NH2, NHR50, N(R50)2, C(0)NH2, C(0)NHR50, C(O)N(R50)2, C(0)NH0H, C(0)NH0R5°, C(0)NHS02R50, C(0)NR50S02R50, S02NH2, S02NHR50, SO2N(R50)2j CFs, CF2CF3j C(0)H, C(0)0H, C(N)NH2j C(N)NHR50, C(N)N(R50)2, OH, (O), CN, N3, N02, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br eller I substituenter; R50 er R51, R52, R53 eller R54; R51 er phenyl, der er ufusioneret eller fusioneret med aren, heteroaren eller R51B; R51B er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R52 er heteroaryl; R53 er C3-C6-cycloalkyl eller C4-C6-cycloalkenyl, der hver har en eller to CH2-dele, der er usubstitueret eller substitueret med uafhængigt udvalgte 0, C(O), CNOH, CNOCH3, S, S(O), S02 eller NH, og en eller to CH-dele, der er usubstitueret eller substitueret med N, og hver er disse er ufusioneret eller fusioneret med aren, heteroaren eller R53B; hvor R53B er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R54 er alkyl, alkenyl eller alkynyl, der hver er usubstitueret eller substitueret med en eller to eller tre uafhængigt udvalgte R55, OR55, SR55, S(0)R55, S02R55, NHR55, N(R55)2, C(0)R55, C(0)NH2, C(0)NHR55, NHC(0)R55, NHS02R55, NHC(0)0R55, S02NH2j S02NHR55, S02N(R55)2j NHC(0)NH2j NHC(0)NHR55, OH, (O), C(0)0H, (O), N3> CN, NH2j CF3j OCF3j CF2CF3j OCF2CF3j F, Cl, Br eller I substituenter; R55 er alkyl, alkenyl, alkynyl, phenyl, heteroaryl eller R56; hvor alkyl, alkenyl, alkynyl er usubstitueret eller substitueret med OCH3; og R56 er C3-C8-cycloalkyl eller C4-C6-cycloalkenyl, der hver har en eller to CH2-dele, der er usubstitueret eller substitueret med uafhængigt udvalgte O, C(O), CNOH, CNOCH3, S, S(O), S02 eller NH, og en eller to CH-dele, der er usubstitueret eller substitueret med N.
4. Forbindelse med formel V
eller terapeutisk acceptabelt salt deraf, hvor R100 er R50, OR50, SR50, S(0)R50, S02R50, C(0)R50, C0(0)R50, 0C(0)R50, 0C(0)0R50, NH2, NHR50, N(R50)2, C(0)NH2, C(0)NHR50, C(O)N(R50)2, C(0)NH0H, C(0)NH0R50, C(0)NHS02R50, C(0)NR55S02R50, S02NH2, S02NHR50, SO2N(R50)2j CF3j CF2CF3j C(0)H, C(0)0H, C(N)NH2j C(N)NHR50, C(N)N(R50)2i OH, (O), CN, N3, N02i CF3i CF2CF3i OCF3i OCF2CF3i F, Cl, Br eller I; n erO, 1,2 eller 3; A1 er N eller C(A2); en eller to eller tre eller hver af A2, B1, D1 og E1 er udvalgt uafhængigt blandt R1, OR1, SR1, S(0)R1, S02R1, C(0)R1, C(0)0R1, 0C(0)R1, NHR1, N(R1)2j C(0)NHR1, C(0)N(R1)2, NHC(0)R1, NHC(0)0R1, NR1C(0)NHR1, NR1C(0)N(R1)2j S02NHR1, S02N(R1)2j NHS02R1, NHS02NHR1 og N(CH3)S02N(CH3)R1, og de resterende af A2, B1, D1 og E1 er udvalgt uafhængigt blandt H, F, Cl, Br, I, CN, CF3, C(0)0H, C(0)NH2 og C(0)0R1A; Y1 er H, CN, N02, C(0)0H, F, Cl, Br, I, CF3, OCF3, CF2CF3, OCF2CF3, R17, OR17, C(0)R17, C(0)0R17, SR17, NH2, NHR17, N(R17)2, NHC(0)R17, C(0)NH2, C(0)NHR17, C(0)N(R17)2, NHS(0)R17 eller NHS02R17; R1 er R2, R3, R4 eller R5; R1A er CrCe-alkyl, C3-C6-alkenyl eller C3-C6-alkynyl; R2 er phenyl, der er ufusioneret eller fusioneret med aren, heteroaren eller R2A; R2A er cycloalkan eller heterocycloalkan; R3 er heteroaryl, der er ufusioneret eller fusioneret med benzen, heteroaren eller R3A; R3A er cycloalkan eller heterocycloalkan; R4 er cycloalkyl, cycloalkenyl, heterocycloalkyl eller heterocycloalkenyl, der hver er ufusioneret eller fusioneret med aren, heteroaren eller R4A; R4A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R5 er alkyl, alkenyl eller alkynyl, der hver er usubstitueret eller substitueret med en eller to eller tre uafhængigt udvalgte R6, R7, OR7, SR7, S(0)R7, S02R7, NHR7, N(R7)2, C(0)R7, C(0)NH2, C(0)NHR7, NHC(0)R7, NHS02R7, NHC(0)0R7, S02NH2, S02NHR7, S02N(R7)2, NHC(0)NH2i NHC(0)NHR7, NHC(0)CH(CH3)NHC(0)CH(CH3)NH2, NHC(0)CH(CH3)NHC(0)CH(CH3)NHR1, OH, (O), C(0)0H, (O), N3, CN, NH2, CF3, CF2CF3, F, Cl, Br eller I substituenter; R6 er C2-C5-spiroalkyl, der hver er usubstitueret eller substitueret med OH, (O), N3, CN, CF3, CF2CF3j F, Cl, Br, I, NH2, NH(CH3) eller N(CH3)2; R7 er R8, R9, R10 eller R11; R8 er phenyl, der er ufusioneret eller fusioneret med aren, heteroaren eller R8A; R8A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R9 er heteroaryl, der er ufusioneret eller fusioneret med aren, heteroaren eller R9A; R9A gr cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R10 er C3-C10-cycloalkyl eller C4-C10-cycloalkenyl, der hver har en eller to CH2-dele, der er usubstitueret eller substitueret med uafhængigt udvalgte O, C(O), CNOH, CNOCH3, S, S(O), S02 eller NH, og en eller to CH-dele, der er usubstitueret eller substitueret med N, og hver er disse er ufusioneret eller fusioneret med aren, heteroaren eller R10A; R10A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R11 er alkyl, alkenyl eller alkynyl, der hver er usubstitueret eller substitueret med en eller to eller tre uafhængigt udvalgte R12, OR12, NHR12, N(R12)2, C(0)NH2, C(0)NHR12, C(0)N(R12)2, OH, (O), C(0)0H, N3, CN, NH2, CF3, CF2CF3, F, Cl, Br eller I substituenter; R12 er R13, R14, R15 eller R16; R13 er phenyl, der er ufusioneret eller fusioneret med aren, heteroaren eller R13A; risa er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R14 er heteroaryl, der hver er ufusioneret eller fusioneret med aren, heteroaren eller R14A; R14A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R15 er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken, der hver er ufusioneret eller fusioneret med aren, heteroaren eller R15A; R15A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R16 er alkyl, alkenyl eller alkynyl; R17 er R18, R19, R20 eller R21; R18 er phenyl, der er ufusioneret eller fusioneret med aren, heteroaren eller R18A; risa er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R19 er heteroaryl, der er ufusioneret eller fusioneret med aren, heteroaren eller R19A; R19A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R20 er C3-Ci0-cycloalkyl eller C4-Ci0-cycloalkenyl, der hver har en eller to CH2-dele, der er usubstitueret eller substitueret med uafhængigt udvalgte O, C(O), CNOH, CNOCH3, S, S(O), S02 eller NH, og en eller to CH-dele, der er usubstitueret eller substitueret med N, og hver er disse er ufusioneret eller fusioneret med aren, heteroaren eller R20A; R20A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R21 er alkyl, alkenyl eller alkynyl, der hver er usubstitueret eller substitueret med en eller to eller tre uafhængigt udvalgte R22, OR22, NHR22, N(R22)2, C(0)NH2, C(0)NHR22, C(0)N(R22)2, OH, (O), C(0)0H, N3, CN, NH2, CF3, CF2CF3, F, Cl, Br eller I substituenter; R22 er R23, R24 eller R25; R23 er phenyl, der er ufusioneret eller fusioneret med aren, heteroaren eller R23A- r23a er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R24 er heteroaren, der er ufusioneret eller fusioneret med aren, heteroaren eller R24A- r24a er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R25 er C3-C6-cycloalkyl eller C4-C6-cycloalkenyl, der hver har en eller to CH2-dele, der er usubstitueret eller substitueret med uafhængigt udvalgte O, C(O), CNOH, CNOCH3, S, S(O), S02 eller NH, og en eller to CH-dele, der er usubstitueret eller substitueret med N, og hver er disse er ufusioneret eller fusioneret med aren, heteroaren eller R25A; R25A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R30 er cycloalkyl eller cycloalkenyl, der hver har en eller to CH2-dele, der er usubstitueret eller substitueret med uafhængigt udvalgte O, C(O), CNOH, CNOCH3, S, S(O), S02 eller NH, og en eller to CH-dele, der er usubstitueret eller substitueret med N, og hver er disse er ufusioneret eller fusioneret med aren, heteroaren eller R30A; R30A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; der hver er substitueret med F, Cl, Br, I, CH2R37, CH(R31)(R37), C(R31)(R31A)(R37), C(0)R37, OR37, SR37, S(0)R37, S02R37, NHR37 eller N(R32)R37; R31 og R31A uafhængigt er F, Cl, Br eller alkyl eller sammen er C2-C5-spiroalkyl; R32 er R33, C(0)R33 eller C(0)0R33; R33 er R34 eller R35; R34 er phenyl, der er ufusioneret eller fusioneret med aryl, heteroaryl eller R34A; R34A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R35 er alkyl, der er usubstitueret eller substitueret med R36; R36 er phenyl, der er ufusioneret eller fusioneret med aren, heteroaren eller R36A- r36a er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R37 er R38, R39 eller R40, der hver er substitueret med F, Cl, Br, I, R41, OR41, NHR41, N(R41)2, NHC(0)0R41, SR41, S(0)R41 eller S02R41; R38 er phenyl, der er ufusioneret eller fusioneret med aren, heteroaren eller R38A- r38a er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R39 er heteroaryl, der er ufusioneret eller fusioneret med aren, heteroaren eller R39A- r39a er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R40 er C3-C8-cycloalkyl eller C4-C8-cycloalkenyl, der hver har en eller to CH2-dele, der er usubstitueret eller substitueret med uafhængigt udvalgte O, C(O), CNOH, CNOCH3, S, S(O), S02 eller NH, og en eller to CH-dele, der er usubstitueret eller substitueret med N, og hver er disse er ufusioneret eller fusioneret med aren, heteroaren eller R40A; R40A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R41 er R42, R43, R44 eller R45; R42 er phenyl, der er ufusioneret eller fusioneret med aren, heteroaren eller R42A; R42A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R43 er heteroaryl, der er ufusioneret eller fusioneret med aren, heteroaren eller R43A- r43a er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R44 er C3-C9-cycloalkyl eller C4-C7-cycloalkenyl, der hver har en eller to CH2-dele, der er usubstitueret eller substitueret med uafhængigt udvalgte O, C(O), CNOH, CNOCH3, S, S(O), S02 eller NH, og en eller to CH-dele, der er usubstitueret eller substitueret med N, og hver er disse er ufusioneret eller fusioneret med aren, heteroaren eller R44A; R44A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R45 er alkyl, alkenyl eller alkynyl, der hver er usubstitueret eller substitueret med en eller to uafhængigt udvalgte R46, OR46, NHR46, N(R46)2, C(0)NH2, C(0)NHR46, C(0)N(R46)2, OH, (O), C(0)0H, N3, CN, NH2, CF3, CF2CF3, F, Cl, Br eller I substituenter; R46 er R47, R48 eller R49; R47 er phenyl, der er ufusioneret eller fusioneret med aren, heteroaren eller R47A. r47a er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R48 er heteroaryl eller R48A; R48A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R49 er C3-C6-cycloalkyl eller C4-C6-cycloalkenyl, der hver har en eller to CH2-dele, der er usubstitueret eller substitueret med uafhængigt udvalgte O, C(O), CNOH, CNOCH3, S, S(O), S02 eller NH, og en eller to CH-dele, der er usubstitueret eller substitueret med N, og hver er disse er ufusioneret eller fusioneret med aren, heteroaren eller R49A; R49A er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; hvor dele som vist ved R2, R3, R4, R6, R6C, R8, R8A, R9, R10, R13, R14, R15, R18, R19, R20, R23, R24, R25, R26, R27, R28, R29, R30, R34, R36, R38, R39, R40, R42, R43, R44, R47, R48 og R49 uafhængigt er usubstitueret, yderligere usubstitueret, substitueret eller yderligere substitueret med en eller to eller tre eller fire eller fem uafhængigt udvalgte R50, OR50, SR50, S(0)R5°, S02R5°, C(0)R5°, C0(0)R5°, 0C(0)R5°, 0C(0)0R5°, NH2, NHR50, N(R50)2, C(0)NH2, C(0)NHR50, C(O)N(R50)2, C(0)NH0H, C(0)NH0R5°, C(0)NHS02R50, C(0)NR50S02R50, S02NH2, S02NHR50, SO2N(R50)2j CF3j CF2CF3j C(0)H, C(0)0H, C(N)NH2j C(N)NHR50, C(N)N(R50)2, OH, (O), CN, N3> N02, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br eller I substituenter; R50 er R51, R52, R53 eller R54; R51 er phenyl, der er ufusioneret eller fusioneret med aren, heteroaren eller R51B; R51B er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R52 er heteroaryl; R53 er C3-C6-cycloalkyl eller C4-C6-cycloalkenyl, der hver har en eller to CH2-dele, der er usubstitueret eller substitueret med uafhængigt udvalgte O, C(O), CNOH, CNOCH3, S, S(O), S02 eller NH, og en eller to CH-dele, der er usubstitueret eller substitueret med N, og hver er disse er ufusioneret eller fusioneret med aren, heteroaren eller R53B; hvor R53B er cycloalkan, cycloalken, heterocycloalkan eller heterocycloalken; R54 er alkyl, alkenyl eller alkynyl, der hver er usubstitueret eller substitueret med en eller to eller tre uafhængigt udvalgte R55, OR55, SR55, S(0)R55, S02R55, NHR55, N(R55)2, C(0)R55, C(0)NH2, C(0)NHR55, NHC(0)R55, NHS02R55, NHC(0)0R55, S02NH2, S02NHR55, S02N(R55)2, NHC(0)NH2, NHC(0)NHR55, OH, (O), C(0)0H, (O), N3, CN, NH2, CF3, OCF3, CF2CF3, OCF2CF3, F, Cl, Br eller I substituenter; R55 er alkyl, alkenyl, alkynyl, phenyl, heteroaryl eller R56; hvor alkyl, alkenyl, alkynyl er usubstitueret eller substitueret med OCH3; og R56 er C3-C8-cycloalkyl eller C4-C6-cycloalkenyl, der hver har en eller to CH2-dele, der er usubstitueret eller substitueret med uafhængigt udvalgte O, C(O), CNOH, CNOCH3, S, S(O), S02 eller NH, og en eller to CH-dele, der er usubstitueret eller substitueret med N.
5. Forbindelse eller terapeutisk acceptabelt salt ifølge et hvilket som helst af kravene 1-4, hvor A1 er C(A2); og A2 erH.
6. Forbindelse eller terapeutisk acceptabelt salt ifølge et hvilket som helst af kravene 1-4, hvor A1 er C(A2) eller N; A2 er Fl; og B1 erNHR1.
7. Forbindelse eller terapeutisk acceptabelt salt ifølge et hvilket som helst af kravene 1-4, hvor A1 er C(A2) eller N; A2 er H; B1 erNHR1; og D1 erH.
8. Forbindelse eller terapeutisk acceptabelt salt ifølge et hvilket som helst af kravene 1-4, hvor A1 er C(A2) eller N; A2 er H; B1 erNHR1; D1 er H; og E1 erH.
9. Forbindelse eller terapeutisk acceptabelt salt ifølge et hvilket som helst af kravene 1-4, hvor A1 er C(A2) eller N; A2 er H; B1 erNHR1; D1 er Η; E1 er H; og Y1 er N02.
10. Forbindelse ifølge krav 1 eller terapeutisk acceptabelt salt deraf, hvor forbindelsen er udvalgt blandt: 4-(4-((2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)- N-((4-((1-cyclopentylpiperidin-4-yl)annino)-3-nitrophenyl)sulfonyl)-2-(1H-indol-5- yloxy)benzamid; 4-(4-((4'-chlor-1,1'-biphenyl-2-yl)methyl)piperazin-1-yl)-2-(1 H-indol-5-yloxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzannid; 4-(4-((4'-chlor-1,1'-biphenyl-2-yl)methyl)piperazin-1-yl)-N-((4-((3-(dimethylamino)propyl)amino)-3-nitrophenyl)sulfonyl )-2-(1 H-indol-5-yloxy)benzamid; 4-(4-((2-(4-chlorphenyl)-5,5-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)- 2-(1 H-indol-5-yloxy)-N-((4-((3-morpholin-4-ylpropyl)amino)-3-nitrophenyl)sulfonyl)benzamid; 4-(4-((2-(4-chlorphenyl)-5,5-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-N-((4-((3-(dimethylamino)propyl)annino)-3-nitrophenyl)sulfonyl)-2-(1 H-indol-5-yloxy)benzamid; 4-(4-((2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)- 2-(1H-indol-5-yloxy)-N-((4-((3-morpholin-4-ylpropyl)amino)-3- nitrophenyl)sulfonyl)benzamid; 4-(4-((2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)- N-((4-((3-(dimethylamino)propyl)amino)-3-nitrophenyl)sulfonyl)-2-(1H-indol-5- yloxy)benzamid; 4-(4-((4'-chlor-1,1'-biphenyl-2-yl)methyl)piperazin-1-yl)-2-(1 H-indol-5-yloxy)-N- ((4-((3-morpholin-4-ylpropyl)amino)-3-nitrophenyl)sulfonyl)benzannid; 4-(4-((4'-chlor-1,1'-biphenyl-2-yl)methyl)piperazin-1-yl)-2-(1H-indol-5-yloxy)-N- ((4-((tetrahydro-2H-pyran-4-ylmethyl)amino)-3- ((trifluormethyl)sulfonyl)phenyl)sulfonyl)benzannid; 4-(4-((4'-chlor-1,1'-biphenyl-2-yl)methyl)piperazin-1-yl)-N-((4-((3-(dimethylamino)propyl)amino)-3-((trifluormethyl)sulfonyl)phenyl)sulfonyl)-2-(1 H-indol-5-yloxy)benzamid; N-((3-((chlor(difluor)methyl)sulfonyl)-4-((3- (dimethylamino)propyl)amino)phenyl)sulfonyl)-4-(4-((2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-(1 H-indol-5-yloxy)benzamid; N-((3-((chlor(difluor)methyl)sulfonyl)-4-((1-methylpiperidin-4-yl)amino)phenyl)sulfonyl)-4-(4-((2-(4-chlorphenyl)-4,4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1 -yl)-2-(1 H-indol-5-yloxy)benzamid; 4-(4-((2-(4-chlorphenyl)cyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-((4-((1-methylpiperidin-4-yl)annino)-3-nitrophenyl)sulfonyl)benzannid; 4-(4-((2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-((4-((1 -methylpiperidin-4-yl)amino)-3-((trifluormethyl)sulfonyl)phenyl)sulfonyl)benzamid; 4-(4-((2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-((4-((2-(4-methylpiperazin-1-yl)ethyl)amino)-3-nitrophenyl)sulfonyl)benzamid; 4-(4-((2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-((4-((3-(4-methylpiperazin-1-yl)propyl)amino)-3-nitrophenyl)sulfonyl)benzamid; 4-(4-((2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-((3-nitro-4-((3-pyrrolidin-1 -ylpropyl)amino)phenyl)sulfonyl)benzamid; 4-(4-((2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-((4-((1 -methylpiperidin-4-yl)annino)-3-nitrophenyl)sulfonyl)benzamid; 4-(4-((2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)- N-((4-(3-(dimethylamino)propoxy)-3-nitrophenyl)sulfonyl)-2-(1H-indol-5- yloxy)benzamid; 4-(4-((2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-((4-(((1-methylpiperidin-4-yl)nnethyl)annino)-3-nitrophenyl)sulfonyl)benzamid; 4-(4-((2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-((4-(4-methylpiperazin-1 -yl)-3-nitrophenyl)sulfonyl)benzamid; 4-(4-((2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-N-((4-(((4-(dimethylamino)-1-methylpiperidin-4-yl)methyl)amino)-3-nitrophenyl)sulfonyl)-2-(1 H-indol-5-yloxy)benzamid; 4-(4-((4'-chlor-4-(2-(dimethylamino)ethoxy)-1,1'-biphenyl-2-yl)methyl)piperazin-1-yl)-2-(1 H-indol-5-yloxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzannid; 4-(4-((4'-chlor-4-(2-morpholin-4-ylethoxy)-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzannid; 4-(4-((4'-chlor-3-(2-(dimethylamino)ethoxy)-1,1'-biphenyl-2-yl)methyl)piperazin- 1-yl)-2-(1H-indol-5-yloxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzannid; 4-(4-((4'-chlor-3-(2-morpholin-4-ylethoxy)-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamid; 4-(4-((4'-chlor-3-(2-(dimethylamino)ethoxy)-1,1'-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-((3-nitro-4-((3-pyrrolidin-1 -ylpropyl)amino)phenyl)sulfonyl)benzamid; 4-(4-((4'-chlor-4-(2-(dimethylamino)ethoxy)-1,1'-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-((3-nitro-4-((3-pyrrolidin-1 -ylpropyl)amino)phenyl)sulfonyl)benzamid; 4-(4-((4'-chlor-4-(2-morpholin-4-ylethoxy)-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-((3-nitro-4-((3-pyrrolidin-1 -ylpropyl)amino)phenyl)sulfonyl)benzamid; 4- (4-((4'-chlor-1,1'-biphenyl-2-yl)methyl)piperazin-1-yl)-2-(2,3-dihydro-1H-indol- 5- yloxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzannid; 4-(4-((4-(4-chlorphenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl)methyl)piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-((4-((1 -methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)benzamid; 4-(4-((2-(4-chlorphenyl)cyclohept-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-((4-((1-methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfc>nyl)benzannid; 4-(4-((2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-N-((4-((3-(dimethylamino)propyl)amino)-3- ((trifluormethyl)sulfonyl)phenyl)sulfonyl)-2-(1H-indol-5-yloxy)benzamid; 4-(4-((2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-N-((4-((3-(dimethylamino)propyl)amino)-3-(trifluormethyl)phenyl)sulfonyl )-2-(1 H-indol-5-yloxy)benzamid; 4-(4-((2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-N-((3-cyano-4-((3-(dimethylamino)propyl)annino)phenyl)sulfonyl)-2-(1 H-indol-5-yloxy)benzamid; 4-(4-((2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-/V-((3-nitro-4-((1-tetrahydro-2/-/-pyran-4-ylpiperidin-4-yl)amino)phenyl)sulfonyl)benzamid; 4-(4-((2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-/V-((4-((4-methylpiperazin-1 -yl)amino)-3-nitrophenyl)sulfonyl)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)benzannid; trans-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin- 1-yl)-2-(1H-indol-5-yloxy)-N-({4-[(4-morpholin-4-ylcyclohexyl)amino]-3- nitrophenyl}sulfonyl)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2- (1H-indol-5-yloxy)-N-({4-[(2-methoxyethyl)amino]-3- nitrophenyl}sulfonyl)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-[(3-nitro-4-{[(3S)-tetrahydro-2H-pyran-3-ylmethyl]amino}phenyl)sulfonyl]benzannid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-[(3-nitro-4-{[(3R)-tetrahydro-2H-pyran-3-ylmethyl]amino}phenyl)sulfonyl]benzannid; 4-(4-{[4-(4-chlorphenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-1-yl)-2-(1 H-indol-5-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-[(4-{[(4-hydroxy-1-methylpiperidin-4-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1 H-indol-5-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-3-fluor-2-(1 H-indol-5-yloxy)-N-({4-[(1-methylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-3-fluor-2-(1 H-indol-5-yloxy)-N-({3-nitro-4-[(1-tetrahydro-2H-pyran-4-ylpiperidin-4-yl)amino]phenyl}sulfonyl)benzamid; N-[(4-{[(3S,4R)-1-benzyl-3-hydroxypiperidin-4-yl]amino}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)benzamid; N-[(4-{[(4-aminotetrahydro-2H-pyran-4-yl)methyl]annino}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-[(4-{[1-(2-methoxyethyl)piperidin-4-yl]annino}-3-nitrophenyl)sulfonyl]benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-5-fluor-2-(1 H-indol-5-yloxy)-N-({4-[(1-methylpiperidin-4-yl)annino]-3-nitrophenyl}sulfonyl)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-5-fluor-2-(1 H-indol-5-yloxy)-N-({3-nitro-4-[(1-tetrahydro-2H-pyran-4-ylpiperidin-4-yl)amino]phenyl}sulfonyl)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)- N-[(4-{[1-(3-hydroxypropyl)piperidin-4-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H- indol-5-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)- N-[(4-{[4-(diethylamino)cyclohexyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-indol-5- yloxy)benzamid; 4- (4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-{[4-({[4-(dimethylamino)tetrahydro-2H-pyran-4-yl]methyl}annino)-3-nitrophenyl]sulfonyl}-2-(1H-indol-5-yloxy)benzamid; N-({4-[(2-aminocyclohexyl)amino]-3-nitrophenyl}sulfonyl)-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol- 5- yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-[(4-{[2-(4-hydroxy-1-methylpiperidin-4-yl)ethyl]amino}-3-nitrophenyl)sulfonyl]-2-(1 H-indol-5-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-[(3-nitro-4-{[1 -(1,3-thiazol-2-yl)piperidin-4-yl]amino}phenyl)sulfonyl]benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)- N-[(4-{[1-(cyclopropylmethyl)pipehdin-4-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H- indol-5-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2- (1H-indol-5-yloxy)-N-[(3-nitro-4-{[1-(4,4,4-trifluorbutyl)piperidin-4- yl]amino}phenyl)sulfonyl]benzamid; 4-[4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl-3-(hydroxymethyl)piperazin-l -yl]-2-(1 H-indol-5-yloxy)-N-({4-[1 -methylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)benzamid; 4-[4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}-3-(hydroxymethyl)piperazin-l -yl]-2-(1 H-indol-5-yloxy)-N-({3-nitro-4-[(1 -tetrahydro-2H-pyran-4-ylpiperidin-4-yl)amino]phenyl}sulfonyl)benzannid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-({4-[(4-methylpiperazin-1 -yl)amino]-3-[(trifluormethyl)sulfonyl]phenyl}sulfonyl)benzannid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-[(3-nitro-4-{[3-(3-oxopiperazin-1 -yl)propyl]amino}phenyl)sulfonyl]benzamid; 4-(4-{[2-(4-chlorphenyl)-5-hydroxycyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-({4-[(1 -methylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)benzamid; 4-(4-{[2-(4-chlorphenyl)-5-hydroxycyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-({3-nitro-4-[(1-tetrahydro-2H-pyran-4-ylpiperidin-4-yl)amino]phenyl}sulfonyl)benzamid; 4-(4-{[2-(4-chlorphenyl)-5-hydroxycyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-({4-[(4-methylpiperazin-1 -yl)amino]-3-nitrophenyl}sulfonyl)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-[(4-{[1 -(2,3-dihydro-1 H-inden-2-yl)piperidin-4-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1 H-indol-5-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-[(4-{[(1-morpholin-4-ylcyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-[(3-nitro-4-{[1 -(1,3-thiazol-2-ylmethyl)piperidin-4-yl]amino}phenyl)sulfonyl]benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-[(3-nitro-4-{[1 -(1,3-thiazol-4-ylmethyl)piperidin-4-yl]amino}phenyl)sulfonyl]benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-{[4-({[4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1 H-indol-5-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-[(4-{[4-(2-hydroxyethyl)piperazin-1-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1 H-indol-5-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-[(4-{[(3S)-1-methylpyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]benzamid; 4- (4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-[(4-{[1 -(3-fluorpropyl)piperidin-4-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1 H-indol- 5- yloxy)benzamid; 4-[4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}-3-(hydroxymethyl)piperazin-1-yl]-2-(1 H-indol-5-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)benzannid; N-[(4-{[(4-aminotetrahydro-2H-pyran-4-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-4-[4-{[2-(4-chlorphenyl )-4,4-dimethylcyclohex-1-en-1-yl]methyl}-3-(hydroxymethyl)piperazin-l -yl]-2-(1 H-indol-5-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-[(4-{[(1-hydroxycyclohexyl)methyl]amino-3-nitrophenyl)sulfonyl]-2-(1H-indol-5-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-[(4-{[4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1 H-indol-5-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-({4-[(2-hydroxy-1-tetrahydro-2H-pyran-4-ylethyl)amino]-3-nitrophenyl}sulfonyl)-2-(1 H-indol-5-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-{[3-nitro-4-({1 -[2-(1 H-pyrazol-1 -yl)ethyl]piperidin-4-yl}amino)phenyl]sulfonyl}benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-{[4-(methylamino)-3-nitrophenyl]sulfonyl}benzannid; 4-(4-{[2-(4-chlorphenyl)-5-hydroxycyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)benzannid; 4- (4-{[2-(4-chlorphenyl)-5-morpholin-4-ylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-2-(1H-indol-5-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)benzannid; N-[(4-{[(1-aminocyclohexyl)methyl]annino}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol- 5- yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-[(3-nitro-4-{[2-(2-oxopyrrolidin-1 -yl)ethyl]amino}phenyl)sulfonyl]benzamid; 4-{4-[1-(4'-chlor-1,1'-biphenyl-2-yl)ethyl]piperazin-1-yl}-2-(1H-indol-5-yloxy)-N- ({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)benzannid; 4-(4-{1 -[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]ethyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)benzamid; 4-(4-{1 -[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]ethyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-({4-[(4-methylpiperazin-1 -yl)amino]-3-nitrophenyl}sulfonyl)benzamid; 4-(4-{1 -[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]ethyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-({4-[(3-morpholin-4-ylpropyl)amino]-3-nitrophenyl}sulfonyl)benzamid; 4-(4-{1 -[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]ethyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-({3-nitro-4-[(1-tetrahydro-2H-pyran-4-ylpiperidin-4-yl)amino]phenyl}sulfonyl)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)- N-({4-[(cyclohexylmethyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-indol-5- yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-{[4-(morpholin-4-ylamino)-3-nitrophenyl]sulfonyl}benzannid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-3-ylmethyl)amino]phenyl}sulfonyl)benzannid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2- (1H-indol-5-yloxy)-N-{[3-nitro-4-(tetrahydro-2H-pyran-4- ylamino)phenyl]sulfonyl}benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2- (1H-indol-5-yloxy)-N-[(4-{[(3-methyloxetan-3-yl)methyl]annino}-3- nitrophenyl)sulfonyl]benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-({4-[(4-methoxycyclohexyl)amino]-3-nitrophenyl}sulfonyl)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-[(4-{[3-(1,1-dioxidothiomorpholin-4-yl)propyl]amino}-3-nitrophenyl)sulfonyl]-2-(1 H-indol-5-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-[(3-nitro-4-{[2-(2-oxopiperidin-1 -yl)ethyl]amino}phenyl)sulfonyl]benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-[(3-nitro-4-{[2-(2-oxoimidazolidin-1 -yl)ethyl]amino}phenyl)sulfonyl]benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-({3-nitro-4-[(2-pyridin-4-ylethyl)amino]phenyl}sulfonyl)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-[(4-morpholin-4-yl-3-nitrophenyl)sulfonyl]benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-{[4-(4-methoxypiperidin-1 -yl)-3-nitrophenyl]sulfonyl}benzamid; 4-(4-{[2-(4-chlorphenyl)-5-pyrrolidin-1 -ylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)benzannid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-[(3-nitro-4-{[2-(3-oxopiperazin-1 -yl)ethyl]amino}phenyl)sulfonyl]benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-[(4-{[(1,1-dioxidotetrahydrothien-3-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1 H-indol-5-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-({4-[(1,1 -dioxidotetrahydrothien-3-yl)amino]-3-nitrophenyl}sulfonyl)-2-(1 H-indol-5-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-{[4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]-3-(thfluormethyl)phenyl]sulfonyl}benzannid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)- N-({4-[2-(1,3-dioxolan-2-yl)ethyl]-3-nitrophenyl}sulfonyl)-2-(1H-indol-5- yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-{[3-nitro-4-(tetrahydro-2H-pyran-4-ylmethoxy)phenyl]sulfonyl}benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-({4-[(1-methyl-5-oxopyrrolidin-3-yl)amino]-3-nitrophenyl}sulfonyl)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-({4-[(1-methyl-6-oxopiperidin-3-yl)amino]-3-nitrophenyl}sulfonyl)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-{[3-nitro-4-(piperidin-1-ylamino)phenyl]sulfonyl}benzannid; 4-(4-{[4-(4-chlorphenyl)-1 -methyl-1 H-pyrazol-5-yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-({4-[(3-methyloxetan-3-yl)methoxy]-3-nitrophenyl}sulfonyl)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-[(3-nitro-4-{[(1-oxidotetrahydro-2H-thiopyran-4-yl)methyl]amino}phenyl)sulfonyl]benzannid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-({3-nitro-4-[(1,3-thiazol-5-ylmethyl)amino]phenyl}sulfonyl)benzannid; 4-(4-{[2-(4-chlorphenyl)-5,5-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2- (1H-indol-5-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl}sulfonyl)benzannid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-({3-nitro-4-[(2-tetrahydro-2H-pyran-4-ylethyl)amino]phenyl}sulfonyl)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-{[3-nitro-4-(2-tetrahydro-2H-pyran-4-ylethyl)phenyl]sulfonyl}benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-{[4-(1,4-dioxan-2-ylmethoxy)-3-nitrophenyl]sulfonyl}-2-(1 H-indol-5-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-[(4-{[2-(2-methoxyethoxy)ethyl]amino}-3-nitrophenyl)sulfonyl]benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-[(3-nitro-4-{[2-(trifluormethoxy)ethyl]annino}phenyl)sulfonyl]benzannid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-({4-[(2,2-difluorethyl)amino]-3-nitrophenyl}sulfonyl)-2-(1 H-indol-5-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2- (1H-indol-5-yloxy)-N-({4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]-3- [(trifluormethyl)sulfonyl]phenyl}sulfonyl)benzannid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-({4-[(4,4-difluorcyclohexyl)amino]-3-nitrophenyl}sulfonyl)-2-(1 H-indol-5-yloxy)benzamid; 4-(4-{[4-(4-chlorphenyl)-1-isopropyl-6-oxo-1,6-dihydropyridin-3-yl]methyl}piperazin-1-yl)-2-(1 H-indol-5-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)benzannid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-[(4-{[(tetrahydro-2H-pyran-4-ylmethyl)amino]carbonyl}phenyl)sulfonyl]benzannid; 4- (4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-[(4-{[(4-hydroxycyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1 H-indol- 5- yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2- (1H-indol-5-yloxy)-N-[(4-{[(4-methoxycyclohexyl)methyl]annino}-3- nitrophenyl)sulfonyl]benzamid; 4-(4-[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-[(4-{[(4-hydroxycyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1 H-indol-5-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-[(4-{[(4-methoxycyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-({4-[(2-methoxyethyl)amino]-3-[(trifluormethyl)sulfonyl]phenyl}sulfonyl)benzannid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-({4-[(3-methoxypropyl)amino]-3-nitrophenyl}sulfonyl)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-({4-[(2-cyanoethyl)amino]-3-nitrophenyl}sulfonyl)-2-(1 H-indol-5-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-{[4-({[(3R)-4-hydroxy-1-adamantyl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1 H-indol-5-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-{[4-({[(3R)-4-hydroxy-1-adamantyl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1 H-indol-5-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-({3-nitro-4-[(3,3,3-trifluorpropyl)amino]phenyl}sulfonyl)benzannid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-({4-[(4-fluortetrahydro-2H-pyran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1 H-indol-5-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-({4-(methylamino)-3-[(trifluormethyl)sulfonyl]phenyl}sulfonyl)benzannid; N-{[5-brom-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3-yl]sulfonyl}-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)benzamid; 4-(4-{[4-(4-chlorphenyl)-6-isopropoxypyridin-3-yl]methyl}piperazin-1-yl)-2-(1 H- indol-5-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl}sulfonyl)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-{[6-(tetrahydro-2H-pyran-4-ylmethoxy)-5-(1,3-thiazol-2-yl)pyridin-3-yl]sulfonyl}benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-[(4-{[(2- methoxyethyl)amino]carbonyl}phenyl)sulfonyl]benzannid; 4- (4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-{[5-cyano-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3-yl]sulfonyl}-2-(1 H-indol-5-yloxy)benzamid; N-({4-[(1-acetylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol- 5- yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2- (1H-indol-5-yloxy)-N-[(4-{[1-(methylsulfonyl)piperidin-4-yl]amino}-3- nitrophenyl)sulfonyl]benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-({4-[(1,4-dioxan-2-ylmethyl)amino]-3-nitrophenyl}sulfonyl)-2-(1 H-indol-5-yloxy)benzamid; 4-(4-{[4'-chlor-5-(trifluormethyl)-1,1 '-biphenyl-2-yl]methyl}piperazin-1 -yl)-2-(1 H- indol-5-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl}sulfonyl)benzannid; 4-(4-{[4'-chlor-5-(trifluormethyl)-1,1 '-biphenyl-2-yl]methyl}piperazin-1 -yl)-2-(1 H- indol-5-yloxy)-N-{[3-nitro-4-(tetrahydro-2H-pyran-4- ylmethoxy)phenyl]sulfonyl}benzamid; 4-{4-[(5-tert-butyl-4'-chlor-1,1 '-biphenyl-2-yl)methyl]piperazin-1 -yl}-2-(1 H-indol-5- yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl}sulfonyl)benzannid; 4-{4-[(5-tert-butyl-4'-chlor-1,1 '-biphenyl-2-yl)methyl]piperazin-1 -yl}-2-(1 H-indol-5- yloxy)-N-{[3-nitro-4-(tetrahydro-2H-pyran-4- ylmethoxy)phenyl]sulfonyl}benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-({3-nitro-4-[(2,2,2-trifluorethyl)amino]phenyl}sulfonyl)benzannid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-[(3-{[(tetrahydro-2H-pyran-4-ylmethyl)amino]carbonyl}phenyl)sulfonyl]benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-({4-[(2R)-1,4-dioxan-2-ylmethoxy]-3-nitrophenyl}sulfonyl)-2-(1 H-indol-5-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-({4-[(2S)-1,4-dioxan-2-ylmethoxy]-3-nitrophenyl}sulfonyl)-2-(1 H-indol-5-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-({4-[(3-morpholin-4-ylpropyl)amino]-3-[(trifluormethyl)sulfonyl]phenyl}sulfonyl)benzannid; N-({5-brom-6-[(tetrahydro-2H-pyran-4-ylmethyl)annino]pyndin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl )-2-(1 H-indol-5-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-({4-[(2-morpholin-4-ylethyl)amino]-3-[(thfluormethyl)sulfonyl]phenyl}sulfonyl)benzannid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-({5-cyano-6-[(tetrahydro-2H-pyran-4-ylmethyl)amino]pyridin-3-yl}sulfonyl)-2-(1 H-indol-5-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-({4-[(1 -methylpiperidin-4-yl)oxy]-3-nitrophenyl}sulfonyl)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-({4-[(1 -methylpiperidin-4-yl)nnethoxy]-3-nitrophenyl}sulfonyl)benzamid; benzyl-4-({[4-({[4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1-en-1- yl]methyl}piperazin-1-yl)-2-(1H-indol-5-yloxy)benzoyl]amino}sulfonyl)-2- nitrophenyl]amino}methyl)piperidin-1-carboxylat; N-{[3-(aminocarbonyl)-4-(tetrahydro-2H-pyran-4-ylmethoxy)phenyl]sulfonyl}-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)benzamid; 4-(4-{[4'-chlor-5-(trifluormethyl)-1,1 '-biphenyl-2-yl]methyl}piperazin-1 -yl)-2-(1 H- indol-5-yloxy)-N-({3-nitro-4-[(1-tetrahydro-2H-pyran-4-ylpiperidin-4- yl)amino]phenyl}sulfonyl)benzamid; 4-{4-[(5-tert-butyl-4'-chlor-1,1 '-biphenyl-2-yl)methyl]piperazin-1 -yl}-2-(1 H-indol-5- yloxy)-N-({3-nitro-4-[(1-tetrahydro-2H-pyran-4-ylpiperidin-4- yl)amino]phenyl}sulfonyl)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methylpiperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-[(4-{[(1 -methyl-1 H-imidazol-5-yl)methyl]amino}-3-nitrophenyl)sulfonyl]benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-{[4-(morpholin-4-ylsulfonyl)phenyl]sulfonyl}benzamid; 4- (4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-({4-[(1,1 -dioxidothiomorpholin-4-yl)amino]-3-nitrophenyl}sulfonyl)-2-(1 H-indol- 5- yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-({4-[(4-morpholin-4-ylcyclohexyl)amino]-3-nitrophenyl}sulfonyl)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-({3-cyano-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1 H-indol-5-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)- N-({4-[(3,3-dimethylbutyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-indol-5- yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-[(4-{[(1S)-1-(hydroxymethyl )-3-methylbutyl]amino}-3-nitrophenyl)sulfonyl]-2-(1 H-indol-5-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-[(3-nitro-4-{[(2R)-tetrahydrofuran-2-ylmethyl]amino}phenyl)sulfonyl]benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-[(4-{[(1 R)-1-(hydroxymethyl)-2-methylpropyl]amino}-3-nitrophenyl)sulfonyl]-2-(1 H-indol-5-yloxy)benzamid; 4- (4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-({4-[(4-methoxyphenyl)amino]-3-nitrophenyl}sulfonyl)benzamid; N-[(4-{[2-(1,3-benzodioxol-5-yl)ethyl]amino}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol- 5- yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-[(3-nitro-4-{[3-(2-oxopyrrolidin-1 -yl)propyl]amino}phenyl)sulfonyl]benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-({4-[(4-hydroxyphenyl)amino]-3-nitrophenyl}sulfonyl)-2-(1 H-indol-5-yloxy)benzamid; N-{[4-({2-[4-(aminosulfonyl)phenyl]ethyl}amino)-3-nitrophenyl]sulfonyl}-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-[(4-{[3-(1 H-imidazol-1 -yl)propyl]amino}-3-nitrophenyl)sulfonyl]-2-(1 H-indol-5-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-[(3-nitro-4-{[(1 S)-1 -phenylethyl]amino}phenyl)sulfonyl]benzamid; N-({2-chlor-5-fluor-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-[(4-{[2-(2-methoxyethoxy)ethyl]thio}-3-nitrophenyl)sulfonyl]benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1H-indol-5-yloxy)-N-{[4-(methylsulfonyl)phenyl]sulfonyl}benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-({4-[(2,2-dimethyltetrahydro-2H-pyran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1 H-indol-5-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-({5-cyano-6-[(4-fluortetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-2-(1 H-indol-5-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)- N-{[5-cyano-6-(2-morpholin-4-ylethoxy)pyridin-3-yl]sulfonyl}-2-(1H-indol-5- yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-({3-nitro-4-[(1-tetrahydro-2H-pyran-4-ylpiperidin-4-yl)oxy]phenyl}sulfonyl)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-5-yloxy)-N-({4-[(4-morpholin-4-ylbut-2-ynyl)oxy]-3-nitrophenyl}sulfonyl)benzamid; og 4- (4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-({4-[(3-hydroxy-4-methoxyphenyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-indol- 5- yloxy)benzamid.
11. Forbindelse ifølge krav 2 eller terapeutisk acceptabelt salt deraf, hvor forbindelsen er udvalgt blandt: 4-(4-((4'-chlor-4-(pyrrolidin-1 -ylmethyl)-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzannid; 4-(4-((4'-chlor-4-(2-pyrrolidin-1 -ylethyl)-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzannid; 4-(4-((4'-chlor-1,1'-biphenyl-2-yl)methyl)piperazin-1-yl)-2-(1H-indol-4-yloxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamid; 4-(4-((4'-chlor-1,1'-biphenyl-2-yl)methyl)piperazin-1-yl)-N-((4-((3-(dimethylamino)propyl)annino)-3-nitrophenyl)sulfonyl )-2-(1 H-indol-4-yloxy)benzamid; 4-(4-((2-(4-chlorphenyl)-5,5-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-((4-((3-morpholin-4-ylpropyl)amino)-3-nitrophenyl)sulfonyl)benzamid; 4-(4-((2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-((4-((3-morpholin-4-ylpropyl)amino)-3-nitrophenyl)sulfonyl)benzamid; 4-(4-((2-(4-chlorphenyl)-5,5-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-N-((4-((3-(dimethylamino)propyl)annino)-3-nitrophenyl)sulfonyl)-2-(1 H-indol-4-yloxy)benzamid; 4-(4-((2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-N-((4-((3-(dimethylamino)propyl)annino)-3-nitrophenyl)sulfonyl)-2-(1 H-indol-4-yloxy)benzamid; 4-(4-((4'-chlor-1,1'-biphenyl-2-yl)methyl)piperazin-1-yl)-2-(1H-indol-4-yloxy)-N- ((4-((3-morpholin-4-ylpropyl)amino)-3-nitrophenyl)sulfonyl)benzannid; 4-(4-((4'-chlor-1,1'-biphenyl-2-yl)methyl)piperazin-1-yl)-2-(1H-indol-4-yloxy)-N- ((4-((tetrahydro-2H-pyran-4-ylmethyl)amino)-3- ((trifluormethyl)sulfonyl)phenyl)sulfonyl)benzamid; 4-(4-((4'-chlor-1,1'-biphenyl-2-yl)methyl)piperazin-1-yl)-2-(1H-indol-4-yloxy)-N- ((4-((3-morpholin-4-ylpropyl)amino)-3- ((trifluormethyl)sulfonyl)phenyl)sulfonyl)benzannid; 2-(1 H-indol-4-yloxy)-4-(4-((2-(4-methoxyphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-N-((3-nitro-4-((3-pyrrolidin-1 -ylpropyl)amino)phenyl)sulfonyl)benzamid; 4-(4-((4,4-dimethyl-2-(4-(thfluormethyl)phenyl)cydohex-1-en-1-yl)methyl)piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-((3-nitro-4-((3-pyrrolidin-1 -ylpropyl)amino)phenyl)sulfonyl)benzamid; 4-(4-((4,4-dimethyl-2-(4-(thfluormethoxy)phenyl)cydohex-1-en-1-yl)methyl)piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-((3-nitro-4-((3-pyrrolidin-1 -ylpropyl)amino)phenyl)sulfonyl)benzamid; 4-(4-((4,4-dimethyl-2-(3-(thfluormethyl)phenyl)cydohex-1-en-1-yl)methyl)piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-((3-nitro-4-((3-pyrrolidin-1 -ylpropyl)amino)phenyl)sulfonyl)benzamid; 4-(4-((2-(3-fluorphenyl)-4,4-dimethylcydohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-((3-nitro-4-((3-pyrrolidin-1 -ylpropyl)amino)phenyl)sulfonyl)benzamid; 4-(4-((2-(4-fluorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-((3-nitro-4-((3-pyrrolidin-1 -ylpropyl)amino)phenyl)sulfonyl)benzamid; 4-(4-((2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-((4-((3-(4-methylpiperazin-1-yl)propyl)amino)-3-nitrophenyl)sulfonyl)benzamid; 4-(4-((2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-((4-((2-(4-methylpiperazin-1-yl)ethyl)amino)-3-nitrophenyl)sulfonyl)benzamid; 4-(4-((2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-((3-nitro-4-((3-pyrrolidin-1 -ylpropyl)amino)phenyl)sulfonyl)benzamid; 4-(4-((2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-((4-((1 -methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)benzamid; 4-(4-((2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-((4-(((1-methylpiperidin-4-yl)methyl)amino)-3-nitrophenyl)sulfonyl)benzamid; 4-(4-((2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-N-((4-(3-(dimethylamino)propoxy)-3-nitrophenyl)sulfonyl)-2-(1 H-indol-4-yloxy)benzamid; 4-(4-((2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)- 2-(1H-indol-4-yloxy)-N-((3-nitro-4-((1-(2,2,2-trifluorethyl)piperidin-4- yl)amino)phenyl)sulfonyl)benzamid; 4-(4-((4'-chlor-4-(2-(dimethylamino)ethoxy)-1,1'-biphenyl-2-yl)nnethyl)piperazin-1-yl)-2-(1 H-indol-4-yloxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzannid; 4-(4-((4'-chlor-3-(2-(dimethylamino)ethoxy)-1,1'-biphenyl-2-yl)methyl)piperazin- 1-yl)-2-(1H-indol-4-yloxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4- ylmethyl)amino)phenyl)sulfonyl)benzannid; 4-(4-((4'-chlor-4-(2-morpholin-4-ylethoxy)-1,1 '-biphenyl-2-yl)methyl)piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamid; 4-(4-((4'-chlor-3-(2-morpholin-4-ylethoxy)-1,1 '-biphenyl-2-y)methyl)piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamid; 4-(4-((2-(4-chlorphenyl)cyclohept-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-((3-nitro-4-((3-pyrrolidin-1-ylpropyl)amino)phenyl)sulfonyl)benzamid; 4-(4-((2-(4-chlorphenyl)cyclooct-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-((3-nitro-4-((3-pyrrolidin-1-ylpropyl)amino)phenyl)sulfonyl)benzamid; 4-(4-((2-(4-chlorphenyl)cyclopent-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-((3-nitro-4-((3-pyrrolidin-1-ylpropyl)amino)phenyl)sulfonyl)benzamid; 4-(4-((2-(4-chlorphenyl)-4,4-dimethylcyclopent-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-((4-((1 -methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)benzamid; 4-(4-((4-(4-chlorphenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl)methyl)piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-((4-((1 -methylpiperidin-4-yl)amino)-3-nitrophenyl)sulfonyl)benzamid; 4-(4-((2-(4-chlorphenyl)cyclooct-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-((4-((1-methylpiperidin-4-yl)annino)-3-nitrophenyl)sulfonyl)benzannid; 4-(4-((2-(4-chlorphenyl)cyclohept-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-((4-((1-methylpiperidin-4-yl)annino)-3-nitrophenyl)sulfonyl)benzannid; 4-(4-((2-(4-chlorphenyl)cyclopent-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-((4-((1-methylpiperidin-4-yl)annino)-3-nitrophenyl)sulfonyl)benzannid; 4-(4-((2-(4-chlorphenyl)cyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-((4-((1-methylpiperidin-4-yl)annino)-3-nitrophenyl)sulfonyl)benzannid; 4-(4-(1 -(4'-chlor-1,1 '-biphenyl-2-yl)ethyl)piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)benzamid; N-((4-(((4-aminotetrahydro-2/-/-pyran-4-yl)methyl)annino)-3-nitrophenyl)sulfonyl)-4-(4-((2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl)methyl)piperazin-1 -yl)-2-(1 H-indol-4-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-[(4-{[(4-hydroxy-1-methylpiperidin-4-yl)methyl]annino}-3-nitrophenyl)sulfonyl]-2-(1 H-indol-4-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-({4-[(4-methylpiperazin-1 -yl)amino]-3-nitrophenyl}sulfonyl)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)- N-[(4-{[1-(2-hydroxyethyl)piperidin-4-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H- indol-4-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-[(4-{[1-(2-methoxyethyl)piperidin-4-yl]amino}-3-nitrophenyl)sulfonyl]benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-[(4-{[1-(3-hydroxypropyl)piperidin-4-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1 H-indol-4-yloxy)benzamid; 4-[4-({4'-chlor-3-[3-(dimethylamino)propyl]-1,1 '-biphenyl-2-yl}methyl)piperazin-1 - yl]-2-(1H-indol-4-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl}sulfonyl)benzannid; 4-{4-[(4'-chlor-4-morpholin-4-yl-1,1 '-biphenyl-2-yl)methyl]piperazin-1 -yl}-2-(1 H- indol-4-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl}sulfonyl)benzamid; 4-[4-({4'-chlor-3-[2-(dimethylamino)ethoxy]-1,1'-biphenyl-2-yl}methyl)piperazin-1 -yl]-2-(1 H-indol-4-yloxy)-N-({3-nitro-4-[(1 -tetrahydro-2H-pyran-4-ylpiperidin-4-yl)amino]phenyl}sulfonyl)benzamid; 4-{4-[1-(4'-chlor-1,1'-biphenyl-2-yl)ethyl]piperazin-1-yl}-2-(1H-indol-4-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)benzannid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-[(4-{[4-(dimethylamino)cyclohexyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-indol-4-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)- N-[(4-{[4-(diethylamino)cyclohexyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-indol-4- yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-({4-[(4-morpholin-4-ylcyclohexyl)amino]-3-nitrophenyl}sulfonyl)benzamid; 4-[4-({4'-chlor-3-[2-(dimethylamino)ethoxy]-1,1'-biphenyl-2-yl}methyl)piperazin-1 -yl]-2-(1 H-indol-4-yloxy)-N-({4-[(1 -methylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)benzamid; 4-{4-[1-(4'-chlor-1,1'-biphenyl-2-yl)ethyl]piperazin-1-yl}-2-(1H-indol-4-yloxy)-N-({4-[(1-methylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)benzannid; 4-[4-({4'-chlor-4-[3-(dimethylamino)prop-1 -ynyl]-1,1 '-biphenyl-2-yl}methyl)piperazin-1-yl]-2-(1H-indol-4-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)benzamid; 4-(4- {[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)- 2-(1H-indol-4-yloxy)-N-[(3-nitro-4-{[1-(4,4,4-trifluorbutyl)piperidin-4- yl]amino}phenyl)sulfonyl]benzamid; 4-(4-{[4'-chlor-4-(2-hydroxyethoxy)-1,1'-biphenyl-2-yl]methyl}piperazin-1-yl)-2-(1 H-indol-4-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-({4-[(4-methylpiperazin-1 -yl)amino]-3-[(trifluormethyl)sulfonyl]phenyl}sulfonyl)benzannid; 4-{4-[1-(4'-chlor-1,1'-biphenyl-2-yl)ethyl]piperazin-1-yl}-2-(1H-indol-4-yloxy)-N-({4-[(4-methylpiperazin-1-yl)amino]-3-nitrophenyl}sulfonyl)benzannid; 4-(4-{[4'-chlor-4-(2-hydroxyethoxy)-1,1'-biphenyl-2-yl]methyl}piperazin-1-yl)-2-(1 H-indol-4-yloxy)-N-({4-[(1 -methylpiperidin-4-yl)annino]-3-nitrophenyl}sulfonyl)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-[(3-nitro-4-{[3-(3-oxopiperazin-1 -yl)propyl]amino}phenyl)sulfonyl]benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-[(4-{[1 -(2,3-dihydro-1 H-inden-2-yl)piperidin-4-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1 H-indol-4-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-({4-[(2-methoxyethyl)amino]-3-nitrophenyl}sulfonyl)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)- N-[(4-{[4-(hydroxymethyl)tetrahydro-2H-pyran-4-yl]amino}-3- nitrophenyl)sulfonyl]-2-(1H-indol-4-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)benzannid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-{[4-(methylamino)-3-nitrophenyl]sulfonyl}benzannid; 4-{4-[1-(4'-chlor-1,1'-biphenyl-2-yl)ethyl]piperazin-1-yl}-2-(1H-indol-4-yloxy)-N-({4-[(3-morpholin-4-ylpropyl)amino]-3-nitrophenyl}sulfonyl)benzamid; 4-{4-[(1 R)-1 -(4'-chlor-1,1'-biphenyl-2-yl)ethyl]piperazin-1 -yl}-2-(1 H-indol-4- yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl}sulfonyl)benzannid; 4-{4-[(1 S)-1 -(4'-chlor-1,1 '-biphenyl-2-yl)ethyl]piperazin-1 -yl}-2-(1 H-indol-4- yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl}sulfonyl)benzannid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1H-indol-4-yloxy)-N-{[4-(morpholin-4-ylamino)-3-nitrophenyl]sulfonyl}benzannid; 4-[4-({4'-chlor-4-[2-(dimethylamino)ethoxy]-1,1'-biphenyl-2-yl}methyl)piperazin-1 -yl]-2-(1 H-indol-4-yloxy)-N-({4-[(4-methylpiperazin-1 -yl)amino]-3-nitrophenyl}sulfonyl)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-[(3-nitro-4-{[2-(3-oxopiperazin-1 -yl)ethyl]amino}phenyl)sulfonyl]benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-{[3-nitro-4-(piperidin-1-ylamino)phenyl]sulfonyl}benzannid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-{[3-nitro-4-(tetrahydro-2H-pyran-4-ylmethoxy)phenyl] sulfonyl} benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-[(3-nitro-4-{[2-(trifluormethoxy)ethyl]annino}phenyl)sulfonyl]benzannid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-[(4-{[2-(2-methoxyethoxy)ethyl]amino}-3-nitrophenyl)sulfonyl]benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-[(4-{[3-(methylsulfonyl)propyl]amino}-3-nitrophenyl)sulfonyl]benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-[(4-{[3-(1,1-dioxidothiomorpholin-4-yl)propyl]amino}-3-nitrophenyl)sulfonyl]-2-(1 H-indol-4-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-({4-[(1,1 -dioxidotetrahydrothien-3-yl)amino]-3-nitrophenyl}sulfonyl)-2-(1 H-indol-4-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-[(4-{[(1,1-dioxidotetrahydro-2H-thiopyran-4-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1 H-indol-4-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-({4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]-3-[(thfluormethyl)sulfonyl]phenyl}sulfonyl)benzannid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-({4-[(4-fluortetrahydro-2H-pyran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1 H-indol-4-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-({4-[(2-methoxyethyl)amino]-3-[(trifluormethyl)sulfonyl]phenyl}sulfonyl)benzannid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-{[3-nitro-4-(2-tetrahydro-2H-pyran-4-ylethoxy)phenyl]sulfonyl}benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2- (1H-indol-4-yloxy)-N-({4-[3-(methylsulfonyl)propoxy]-3- nitrophenyl}sulfonyl)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-({4-[(3-methoxypropyl)amino]-3-nitrophenyl}sulfonyl)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-({4-[(2-cyanoethyl)amino]-3-nitrophenyl}sulfonyl)-2-(1 H-indol-4-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2- (1H-indol-4-yloxy)-N-({3-nitro-4·!^^- trifluorpropyl)amino]phenyl}sulfonyl)benzannid; N-({5-brom-6-[(tetrahydro-2H-pyran-4-ylmethyl)amino]pyndin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl )-2-(1 H-indol-4-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-[(4-{[(1,1-dioxidotetrahydrothien-3-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1 H-indol-4-yloxy)benzamid; N-({4-[(1-acetylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-4-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-[(4-{[1-(methylsulfonyl)piperidin-4-yl]amino}-3-nitrophenyl)sulfonyl]benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-({3-nitro-4-[(2,2,2-trifluorethyl)amino]phenyl}sulfonyl)benzannid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-({4-[(3-morpholin-4-ylpropyl)amino]-3-[(trifluormethyl)sulfonyl]phenyl}sulfonyl)benzannid; 4-(4-{[4-(4-chlorphenyl)-1-(3-hydroxypropyl)-1,2,5,6-tetrahydropyridin-3-yl]methyl}piperazin-1-yl)-2-(1 H-indol-4-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)benzannid; N-{[5-brom-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3-yl]sulfonyl}-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-4-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-{[6-[(tetrahydro-2H-pyran-4-ylmethyl)amino]-5-(1,3-thiazol-2-yl)pyridin-3-yl]sulfonyl}benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-({3-cyano-4-[(tetrahydro-2H-pyran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1 H-indol-4-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-[(4-{[2-(2-methoxyethoxy)ethyl]thio}-3-nitrophenyl)sulfonyl]benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-4-yloxy)-N-{[4-(methylsulfonyl)phenyl]sulfonyl}benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-{[5-cyano-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3-yl]sulfonyl}-2-(1 H-indol-4-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-{[5-chlor-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3-yl]sulfonyl}-2-(1 H-indol-4-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-{[5-ethynyl-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3-yl]sulfonyl}-2-(1 H-indol-4-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)- N-{[5-cyano-6-(2-morpholin-4-ylethoxy)pyridin-3-yl]sulfonyl}-2-(1H-indol-4- yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-({5-cyano-6-[(4-fluortetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-2-(1 H-indol-4-yloxy)benzamid; og N-({5-chlor-6-[(4-fluortetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indol-4-yloxy)benzamid.
12. Forbindelse ifølge krav 3 eller terapeutisk acceptabelt salt deraf, hvor forbindelsen er udvalgt blandt: 2-(1 H-benzimidazol-4-yloxy)-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1- en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-pyran-4- ylmethyl)amino]phenyl}sulfonyl)benzannid; 2-(1 H-benzimidazol-4-yloxy)-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1-en-1 -yl]methyl}piperazin-1 -yl)-N-[(4-{[(3R)-1 -(2,2-difluorethyl)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]benzamid; 2- (1 H-benzimidazol-4-yloxy)-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-N-({4-[(4-fluortetrahydro-2H-pyran-4-yl)methoxy]- 3- nitrophenyl}sulfonyl)benzamid; 2-(1H-benzimidazol-4-yloxy)-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1- en-1-yl]methyl}piperazin-1-yl)-N-{[4-({[4-(2,2-difluorethyl)morpholin-2- yl]methyl}amino)-3-nitrophenyl]sulfonyl}benzamid; 2-(1 H-benzimidazol-4-yloxy)-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1-en-1 -yl]methyl}piperazin-1 -yl)-N-({3-nitro-4-[(1 -tetrahydro-2H-pyran-4-ylpiperidin-4-yl)amino]phenyl}sulfonyl)benzamid; 2-(1 H-benzimidazol-4-yloxy)-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1-en-1 -yl]methyl}piperazin-1 -yl)-N-({4-[(1 -methylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)benzamid; 2-(1 H-benzimidazol-4-yloxy)-N-[(5-chlor-6-{[(2S)-4-(N,N-dimethylglycyl)morpholin-2-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)benzamid; 2-(1 H-benzimidazol-4-yloxy)-N-[(5-chlor-6-{[(2R)-4-(N,N-dimethylglycyl)morpholin-2-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)benzamid; 2-(1H-benzimidazol-4-yloxy)-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1-en-1 -yl]methyl}piperazin-1 -yl)-N-[(4-{[(3R)-1 -(cyanomethyl)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]benzamid; 2-(1H-benzimidazol-4-yloxy)-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1-en-1 -yl]methyl}piperazin-1 -yl)-N-{[4-({(3R)-1 -[2-(2- methoxyethoxy)ethyl]pyrrolidin-3-yl}amino)-3-nitrophenyl]sulfonyl}benzannid; 2-(1 H-benzimidazol-4-yloxy)-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1-en-1 -yl]methyl}piperazin-1 -yl)-N-[(4-{[(3R)-1 -(N,N-dimethylglycyl)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]benzamid; 2-(1 H-benzimidazol-4-yloxy)-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1- en-1-yl]methyl}piperazin-1-yl)-N-{[4-({[4-(cyanomethyl)nnorpholin-2- yl]methyl}amino)-3-nitrophenyl]sulfonyl}benzamid; 2-(1 H-benzimidazol-4-yloxy)-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1- en-1-yl]methyl}piperazin-1-yl)-N-[(4-{[(4-cyclopropylmorpholin-2- yl)methyl]amino}-3-nitrophenyl)sulfonyl]benzamid; 2-(1 H-benzimidazol-4-yloxy)-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1- en-1-yl]methyl}piperazin-1-yl)-N-[(3-nitro-4-{[(4-oxetan-3-ylmorpholin-2- yl)methyl]amino}phenyl)sulfonyl]benzamid; 2-(1H-benzimidazol-4-yloxy)-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1- en-1-yl]methyl}piperazin-1-yl)-N-{[4-({[(2R)-4-(N,N-dimethylglycyl)morpholin-2- yl]methyl}amino)-3-nitrophenyl]sulfonyl}benzamid; 2-(1 H-benzimidazol-4-yloxy)-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1- en-1-yl]methyl}piperazin-1-yl)-N-{[4-({[(2S)-4-(N,N-dimethylglycyl)morpholin-2- yl]methyl}amino)-3-nitrophenyl]sulfonyl}benzamid; 2-(1 H-benzimidazol-4-yloxy)-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1- en-1-yl]methyl}piperazin-1-yl)-N-({3-nitro-4-[(tetrahydrofuran-3- ylmethyl)amino]phenyl}sulfonyl)benzamid; trans-2-(1 H-benzimidazol-4-yloxy)-4-(4-{[2-(4-chlorphenyl)-4,4- dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-[(4-{[(4- methoxycyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]benzamid; 2-(1 H-benzimidazol-4-yloxy)-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1- en-1-yl]methyl}piperazin-1-yl)-N-[(4-{[(4-fluortetrahydro-2H-pyran-4- yl)methyl]amino}-3-nitrophenyl)sulfonyl]benzamid; 2-(1H-benzimidazol-4-yloxy)-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1- en-1-yl]methyl}piperazin-1-yl)-N-({5-fluor-6-[(4-fluortetrahydro-2H-pyran-4- yl)methoxy]pyridin-3-yl}sulfonyl)benzamid; 2-(1H-benzimidazol-4-yloxy)-N-({5-chlor-6-[(4-fluortetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)benzamid; 2-(1 H-benzimidazol-4-yloxy)-N-({5-chlor-6-[(1-cyclopropylpiperidin-4-yl)amino]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1-en-1 -yl]methyl}piperazin-1 -yl)benzamid; 2-(1 H-benzimidazol-4-yloxy)-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1-en-1 -yl]methyl}piperazin-1 -yl)-N-({4-[(1,4-dioxan-2-ylmethyl)amino]-3-nitrophenyl}sulfonyl)benzamid; 2-(1 H-benzimidazol-4-yloxy)-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1-en-1 -yl]methyl}piperazin-1 -yl)-N-({4-[(1 -cyclopropylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)benzamid; trans-2-(1 H-benzimidazol-4-yloxy)-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-({4-[(4-morpholin-4-ylcydohexyl)amino]-3-nitrophenyl}sulfonyl)benzamid; 2-(1H-benzimidazol-4-yloxy)-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1-en-1 -yl]methyl}piperazin-1 -yl)-N-({4-[(4-methylpiperazin-1 -yl)amino]-3-nitrophenyl}sulfonyl)benzamid; 2-(1 H-benzimidazol-4-yloxy)-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1-en-1 -yl]methyl}piperazin-1 -yl)-N-[(4-{[(1 -methylpiperidin-4-yl)methyl]amino}-3-nitrophenyl)sulfonyl]benzamid; 2-(1 H-benzimidazol-4-yloxy)-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1-en-1 -yl]methyl}piperazin-1 -yl)-N-({4-[({(2R)-4-[2-(2-methoxyethoxy)ethyl]morpholin-2-yl}methyl)amino]-3-nitrophenyl}sulfonyl)benzamid; 2-(1 H-benzimidazol-4-yloxy)-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1- en-1-yl]methyl}piperazin-1-yl)-N-[(4-{[(4,4-difluorcyclohexyl)methyl]amino}-3- nitrophenyl)sulfonyl]benzamid; N-[(4-{[(4-acetylmorpholin-2-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1 H- benzimidazol-4-yloxy)-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1-en-1- yl]methyl}piperazin-1-yl)benzamid; 2-(1 H-benzimidazol-4-yloxy)-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1- en-1-yl]methyl}piperazin-1-yl)-N-{[4-({[4-(methylsulfonyl)morpholin-2- yl]methyl}amino)-3-nitrophenyl]sulfonyl}benzamid; trans-2-(1 H-benzimidazol-4-yloxy)-4-(4-{[2-(4-chlorphenyl)-4,4- dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-[(4-{[(4- cyanocyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]benzannid; og 2-(1H-benzimidazol-4-yloxy)-N-({5-chlor-6-[(4,4- difluorcyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)benzamid.
13. Forbindelse ifølge krav 4 eller terapeutisk acceptabelt salt deraf, hvor forbindelsen er udvalgt blandt: N-({5-chlor-6-[(4-fluortetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indazol-4-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-({5-cyano-6-[(4-fluortetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-2-(1 H-indazol-4-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-[(4-{[(4-fluortetrahydro-2H-pyran-4-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1 H-indazol-4-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)- N-{[6-[(4-fluortetrahydro-2H-pyran-4-yl)methoxy]-5-(trifluormethyl)pyridin-3- yl]sulfonyl}-2-(1H-indazol-4-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-[(4-{[(4-cyclopropylmorpholin-2-yl)methyl]annino}-3-nitrophenyl)sulfonyl]-2-(1 H-indazol-4-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-[(4-{[(4,4-difluorcyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1 H-indazol-4-yloxy)benzamid; N-[(5-chlor-6-{[(4-fluortetrahydro-2H-pyran-4-yl)methyl]amino}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1 -yl)-2-(1 H-indazol-4-yloxy)benzamid; trans-N-({5-chlor-6-[(4-methoxycyclohexyl)methoxy]pyridin-3-yl}sulfonyl )-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl )-2-(1 H-indazol-4-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-({5-fluor-6-[(4-fluortetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-2-(1 H-indazol-4-yloxy)benzamid; N-[(5-chlor-6-{[1-(cyanomethyl)-4-fluorpiperidin-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1 -yl)-2-(1 H-indazol-4-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-{[5-chlor-6-(tetrahydrofuran-3-ylmethoxy)pyridin-3-yl]sulfonyl}-2-(1 H-indazol-4-yloxy)benzamid; trans-N-({5-chlor-6-[(4-hydroxycyclohexyl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl )-2-(1 H-indazol-4-yloxy)benzamid; N-[(5-chlor-6-{[(3R)-1-(2,2-difluorethyl)pyrrolidin-3-yl]oxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indazol-4-yloxy)benzamid; N-[(5-chlor-6-{[(2S)-4-(N,N-dimethylglycyl)morpholin-2-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1 -yl)-2-(1 H-indazol-4-yloxy)benzamid; N-[(5-chlor-6-{[(2R)-4-(N,N-dimethylglycyl)morpholin-2-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1 -yl)-2-(1 H-indazol-4-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-{[5-chlor-6-(tetrahydro-2H-pyran-4-ylmethoxy)pyridin-3-yl]sulfonyl}-2-(1 H-indazol-4-yloxy)benzamid; N-{[5-chlor-6-({(3R)-1-[2-fluor-1-(fluormethyl)ethyl]pyrrolidin-3-yl}oxy)pyridin-3-yl]sulfonyl}-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1 -yl)-2-(1 H-indazol-4-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-{[4-({(3R)-1-[2-fluor-1-(fluormethyl)ethyl]pyrrolidin-3-yl}amino)-3-nitrophenyl]sulfonyl}-2-(1 H-indazol-4-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-({4-[(1-cyclopropylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl )-2-(1 H-indazol-4-yloxy)benzamid; N-{[5-chlor-6-({(3R)-1-[2-fluor-1-(fluormethyl)ethyl]pyrrolidin-3-yl}methoxy)pyridin-3-yl]sulfonyl}-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indazol-4-yloxy)benzamid; N-[(5-chlor-6-{[(3R)-1-(2,2-difluorethyl)pyrrolidin-3-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1 -yl)-2-(1 H-indazol-4-yloxy)benzamid; trans-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1-en-1-yl]methyl}piperazin-1-yl)-2-(1 H-indazol-4-yloxy)-N-[(4-{[(4-methoxycyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-{[4-(1,4-dioxan-2-ylmethoxy)-3-nitrophenyl]sulfonyl}-2-(1 H-indazol-4-yloxy)benzamid; N-({5-chlor-6-[(1-cyclopropylpiperidin-4-yl)amino]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-2-(1 H-indazol-4-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-{[6-({4-fluor-1-[2-fluor-1-(fluornnethyl)ethyl]piperidin-4-yl}nnethoxy)-5-(trifluormethyl)pyridin-3-yl]sulfonyl}-2-(1 H-indazol-4-yloxy)benzamid; 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-{[5-chlor-6-(2-tetrahydrofuran-2-ylethoxy)pyridin-3-yl]sulfonyl}-2-(1H-indazol-4-yloxy)benzamid; N-({3-chlor-4-[(4-fluortetrahydro-2H-pyran-4-yl)methoxy]phenyl}sulfonyl)-4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl )-2-(1 H-indazol-4-yloxy)benzamid; N-({5-chlor-6-[(4-fluortetrahydro-2H-pyran-4-yl)methoxy]pyridin-3-yl}sulfonyl)-4-(4-{[4-(4-chlorphenyl)-6,6-dimethyl-5,6-dihydro-2H-pyran-3-yl]methyl}piperazin-1 -yl)-2-(1 H-indazol-4-yloxy)benzamid; og 4-(4-{[2-(4-chlorphenyl)-4,4-dimethylcyclohex-1 -en-1 -yl]methyl}piperazin-1 -yl)-N-{[5-cyano-6-(2-tetrahydro-2H-pyran-4-ylethoxy)pyridin-3-yl]sulfonyl}-2-(1 H-indazol-4-yloxy)benzamid.
14. Sammensætning til anvendelse til behandling af blærecancer, hjernecancer, brystcancer, knoglemarvscancer, cervikal cancer, kronisk lymfocytisk leukæmi, kolorektal cancer, øsofageal cancer, hepatocellulær cancer, lymfoblastisk leukæmi, follikulært lymfom, en lymfoid malignitet af T-celle- eller B-celle-oprindelse, melanom, myeloid leukæmi, myelom, oral cancer, ovariecancer, ikke-småcellet lungecancer, prostatacancer, småcellet lungecancer eller miltcancer, hvilken sammensætning omfatter et excipiens og en terapeutisk effektiv mængde af forbindelsen eller det terapeutisk acceptable salt ifølge et hvilket som helst af kravene 1-13.
15. Forbindelse eller terapeutisk acceptabelt salt ifølge et hvilket som helst af kravene 1-13 til anvendelse til behandling af blærecancer, hjernecancer, brystcancer, knoglemarvscancer, cervikal cancer, kronisk lymfocytisk leukæmi, kolorektal cancer, øsofageal cancer, hepatocellulær cancer, lymfoblastisk leukæmi, follikulært lymfom, en lymfoid malignitet af T-celle- eller B-celle-oprindelse, melanom, myeloid leukæmi, myelom, oral cancer, ovariecancer, ikke-småcellet lungecancer, prostatacancer, småcellet lungecancer eller miltcancer hos en patient.
DK09795606.4T 2008-12-05 2009-12-04 Sulfonamidderivater som bcl-2-selektive apoptoseinducerende midler til behandling af cancer og immunsygdomme DK2376480T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12027508P 2008-12-05 2008-12-05
US18118009P 2009-05-26 2009-05-26
PCT/US2009/066790 WO2010065865A2 (en) 2008-12-05 2009-12-04 Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases

Publications (1)

Publication Number Publication Date
DK2376480T3 true DK2376480T3 (da) 2016-09-12

Family

ID=41786218

Family Applications (1)

Application Number Title Priority Date Filing Date
DK09795606.4T DK2376480T3 (da) 2008-12-05 2009-12-04 Sulfonamidderivater som bcl-2-selektive apoptoseinducerende midler til behandling af cancer og immunsygdomme

Country Status (38)

Country Link
EP (3) EP2376480B1 (da)
JP (2) JP5684720B2 (da)
KR (2) KR101692705B1 (da)
CN (2) CN102307872B (da)
AR (1) AR074510A1 (da)
AU (1) AU2009322219B2 (da)
BR (1) BRPI0922771A2 (da)
CA (1) CA2744711C (da)
CL (1) CL2011001313A1 (da)
CO (1) CO6390038A2 (da)
CR (2) CR20160269A (da)
CY (1) CY1117929T1 (da)
DK (1) DK2376480T3 (da)
DO (1) DOP2011000152A (da)
EC (1) ECSP11011174A (da)
ES (1) ES2588374T3 (da)
HK (1) HK1162031A1 (da)
HR (1) HRP20161085T1 (da)
HU (1) HUE029289T2 (da)
IL (2) IL212960A (da)
LT (1) LT2376480T (da)
ME (1) ME02642B (da)
MX (2) MX2011005922A (da)
MY (1) MY158932A (da)
NZ (2) NZ614305A (da)
PE (2) PE20120119A1 (da)
PH (1) PH12015502581B1 (da)
PL (1) PL2376480T3 (da)
PT (1) PT2376480T (da)
RS (1) RS55176B1 (da)
RU (2) RU2497822C2 (da)
SG (1) SG10201500767RA (da)
SI (1) SI2376480T1 (da)
SM (1) SMT201600313B (da)
TW (2) TWI600652B (da)
UY (2) UY32305A (da)
WO (1) WO2010065865A2 (da)
ZA (1) ZA201103806B (da)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100160322A1 (en) 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8557983B2 (en) 2008-12-04 2013-10-15 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8563735B2 (en) 2008-12-05 2013-10-22 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US8586754B2 (en) 2008-12-05 2013-11-19 Abbvie Inc. BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
NZ593593A (en) 2009-01-19 2013-11-29 Abbvie Inc Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
HUE027698T2 (en) 2009-05-26 2016-10-28 Abbvie Bahamas Ltd Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
US9034875B2 (en) 2009-05-26 2015-05-19 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US20220315555A1 (en) 2009-05-26 2022-10-06 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
TWI520960B (zh) * 2010-05-26 2016-02-11 艾伯維有限公司 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑
TWI535712B (zh) * 2010-08-06 2016-06-01 阿斯特捷利康公司 化合物
UA113500C2 (xx) * 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
CA3152557A1 (en) 2010-10-29 2012-05-03 Abbvie Inc. Solid dispersions containing an apoptosis-inducing agent
MY191300A (en) * 2010-11-23 2022-06-14 Abbvie Ireland Unlimited Co Methods of treatment using selective bcl-2 inhibitors
JP6141188B2 (ja) 2010-11-23 2017-06-07 アッヴィ・インコーポレイテッド アポトーシス誘導剤の塩および結晶の形態
CN103987711B (zh) 2011-10-14 2016-08-24 艾伯维公司 作为用于治疗癌症和免疫性和自身免疫性疾病的凋亡诱导剂的8-氨基甲酰基-2-(2,3-二取代吡啶-6-基)-1,2,3,4-四氢异喹啉衍生物
WO2013185202A1 (en) * 2012-06-14 2013-12-19 Beta Pharma Canada Inc Apoptosis inducers
ES2800026T3 (es) 2012-08-09 2020-12-23 Celgene Corp Tratamiento de enfermedades inmunitarias e inflamatorias
US20150038511A1 (en) 2012-08-09 2015-02-05 Celgene Corporation Treatment of immune-related and inflammatory diseases
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
TWI745271B (zh) 2014-05-19 2021-11-11 美商西建公司 全身紅斑性狼瘡之治療
CN104402778B (zh) * 2014-12-03 2017-04-05 青岛蓝帆新材料有限公司 一种苄磺酰胺取代的丙烯酰胺衍生物
US10195213B2 (en) 2015-03-13 2019-02-05 Unity Biotechnology, Inc. Chemical entities that kill senescent cells for use in treating age-related disease
CN105198789B (zh) * 2015-10-26 2018-06-05 山东大学 取代3-吲哚类Bcl-2蛋白抑制剂及制备方法和应用
US11111259B2 (en) 2015-12-18 2021-09-07 Unity Biotechnology, Inc. Acylsulfonamide derivatives for treating senescence-associated diseases and disorders
EP4129999A1 (en) 2016-08-05 2023-02-08 The Regents Of The University Of Michigan N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors
US11053239B2 (en) 2017-01-07 2021-07-06 Fochon Pharmaceuticals, Ltd. Compounds as BLC-2-selective apoptosis-inducing agents
JOP20190191A1 (ar) 2017-02-22 2019-08-08 Astrazeneca Ab وحدات شجرية علاجية
CN110546151B (zh) 2017-04-18 2023-04-28 重庆复创医药研究有限公司 凋亡诱导剂
ES2971457T3 (es) 2017-08-23 2024-06-05 Guangzhou Lupeng Pharmaceutical Company Ltd Inhibidores de BCL-2
AU2019207608B2 (en) * 2018-01-10 2024-03-28 Recurium Ip Holdings, Llc Benzamide compounds
WO2019185025A1 (zh) * 2018-03-30 2019-10-03 正大天晴药业集团股份有限公司 三氟甲基取代的磺酰胺类选择性bcl-2抑制剂
CA3098348A1 (en) 2018-04-29 2019-11-07 Beigene, Ltd. Bcl-2 inhibitors
CA3095699A1 (en) 2018-07-31 2020-02-06 Ascentage Pharma (Suzhou) Co., Ltd. Combination product of bcl-2 inhibitor and chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases
KR20210003731A (ko) 2018-07-31 2021-01-12 어센테지 파마 (쑤저우) 컴퍼니 리미티드 Bcl-2 억제제와 MDM2 억제제의 병용 제품 및 질환의 예방 및/또는 치료에 있어서 이의 용도
US11554127B2 (en) 2018-07-31 2023-01-17 Ascentage Pharma (Suzhou) Co., Ltd. Synergistic antitumor effect of Bcl-2 inhibitor combined with rituximab and/or bendamustine or Bcl-2 inhibitor combined with CHOP
CN110772521A (zh) 2018-07-31 2020-02-11 苏州亚盛药业有限公司 Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途
US11903950B2 (en) 2018-08-22 2024-02-20 Newave Pharmaceutical Inc. BCL-2 inhibitors
KR20210086680A (ko) * 2018-10-29 2021-07-08 치아타이 티안큉 파마수티컬 그룹 주식회사 Bcl-2-선택적 억제제로서의 트리플루오로메틸-치환된 술폰아미드
CN109384764B (zh) * 2018-12-12 2021-09-03 中国科学院上海有机化学研究所 苯基噻吩磺酰胺类化合物、药物组合物、其制备方法和应用
CN109851535A (zh) * 2019-01-30 2019-06-07 天津现代职业技术学院 一种制备4-氟-3-(三氟甲磺酰基)苯磺酰胺的方法
WO2020238785A1 (zh) 2019-05-24 2020-12-03 正大天晴药业集团股份有限公司 包括甲基和三氟甲基的双取代磺酰胺类选择性bcl-2抑制剂
US20230174528A1 (en) 2020-04-29 2023-06-08 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Crystal of trifluoromethyl/chloro disubstituted sulfonamide selective bcl-2 inhibitor
CN111848607B (zh) * 2020-07-22 2023-03-17 长沙创新药物工业技术研究院有限公司 一种新型bcl-2/bcl-xl抑制剂、药物组合物及用途
JP2024504542A (ja) * 2021-02-01 2024-02-01 アセンテージ ファーマ（スーチョウ）カンパニー，リミティド Ｂｃｌ－２阻害剤としてのスルホニルベンズアミド誘導体
EP4353722A1 (en) 2021-06-04 2024-04-17 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Phosphate of trifluoromethyl-substituted sulfonamide compound
KR20230144443A (ko) 2022-04-06 2023-10-16 한국과학기술원 MCL-1 및 BCL-xL에 동시에 결합하는 단백질 및 이의 용도
WO2024012557A1 (en) * 2022-07-15 2024-01-18 Berrybio (Hong Kong) Limited Anti-apoptotic bcl-2 family protein degraders, pharmaceutical compositions, and therapeutic applications
WO2024032776A1 (en) * 2022-08-12 2024-02-15 Fochon Biosciences, Ltd. Compounds as bcl-2 inhibitors

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4215878A1 (de) * 1992-05-14 1993-11-18 Bayer Ag Sulfonylierte Carbonsäureamide
GB9203798D0 (en) * 1992-02-21 1992-04-08 Fujisawa Pharmaceutical Co Quinolylbenzofuran derivatives,processes for preparation thereof and pharmaceutical composition comprising the same
MY115155A (en) 1993-09-09 2003-04-30 Upjohn Co Substituted oxazine and thiazine oxazolidinone antimicrobials.
ATE257829T1 (de) 1995-09-15 2004-01-15 Upjohn Co Aminoaryl oxazolidinone n-oxide
US20030220234A1 (en) 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
RU2208609C2 (ru) * 1998-02-04 2003-07-20 Новартис Аг Сульфониламинопроизводные, которые ингибируют разлагающие матрикс металлопротеиназы
DE19830430A1 (de) * 1998-07-08 2000-01-13 Hoechst Marion Roussel De Gmbh Schwefelsubstituierte Sulfonylamino-carbonsäure-N-arylamide, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
GB9918037D0 (en) 1999-07-30 1999-09-29 Biochemie Gmbh Organic compounds
ES2249270T3 (es) * 1999-08-12 2006-04-01 Pharmacia Italia S.P.A. Derivados de 3(5)-aminopirazol, procedimiento para su preparacion y su uso como agentes antitumorales.
PL365444A1 (en) * 2000-03-21 2005-01-10 The Procter & Gamble Company Heterocyclic side chain containing, n-substituted metalloprotease inhibitors
AR031130A1 (es) * 2000-09-20 2003-09-10 Abbott Lab N-acilsulfonamidas promotoras de la apoptosis
US6720338B2 (en) * 2000-09-20 2004-04-13 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US6995162B2 (en) * 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
AR036608A1 (es) * 2001-09-24 2004-09-22 Bayer Corp Derivados de imidazol, composiciones farmaceuticas y el uso de dichos derivados para la fabricacion de un medicamento para el tratamiento de la obesidad
EA009201B1 (ru) * 2003-09-03 2007-12-28 Пфайзер Инк. Фенил - или пиридиламидные соединения в качестве антагонистов простагландина e2
JP4336678B2 (ja) 2003-09-04 2009-09-30 株式会社日立超エル・エス・アイ・システムズ 半導体装置
US7973161B2 (en) 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
US8614318B2 (en) * 2003-11-13 2013-12-24 Abbvie Inc. Apoptosis promoters
WO2005049593A2 (en) * 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
DE602004009344T2 (de) 2004-04-19 2008-07-10 Symed Labs Ltd., Hyderabad Neues verfahren zur herstellung von linezolid und verwandten verbindungen
ES2382383T3 (es) * 2004-06-17 2012-06-07 Infinity Discovery, Inc. Compuestos y procedimientos para inhibir la interacción de proteínas Bcl con componentes de unión
ATE429423T1 (de) 2004-07-20 2009-05-15 Symed Labs Ltd Neue zwischenprodukte für linezolid und verwandte verbindungen
ZA200702257B (en) * 2004-08-20 2009-06-24 Univ Michigan Small molecule inhibitors of anti-apoptotic BCL-2 family members and the uses thereof
WO2006039164A2 (en) 2004-09-29 2006-04-13 Amr Technology, Inc. Novel cyclosporin analogues and their pharmaceutical uses
PT1888550E (pt) * 2005-05-12 2014-09-03 Abbvie Bahamas Ltd Promotores de apoptose
TW200716636A (en) 2005-05-31 2007-05-01 Speedel Experimenta Ag Heterocyclic spiro-compounds
US7514068B2 (en) 2005-09-14 2009-04-07 Concert Pharmaceuticals Inc. Biphenyl-pyrazolecarboxamide compounds
CN101534904B (zh) * 2006-09-05 2013-11-06 Abbvie公司 治疗血小板过量的bcl抑制剂
US8796267B2 (en) 2006-10-23 2014-08-05 Concert Pharmaceuticals, Inc. Oxazolidinone derivatives and methods of use
WO2008064116A2 (en) 2006-11-16 2008-05-29 Abbott Laboratories Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection
MX2009008465A (es) 2007-02-15 2009-08-20 Hoffmann La Roche Nuevas 2-aminooxazolinas como ligandos de taar1.
WO2008131259A1 (en) 2007-04-19 2008-10-30 Concert Pharmaceuticals Inc. Deuterated morpholinyl compounds
US7531685B2 (en) 2007-06-01 2009-05-12 Protia, Llc Deuterium-enriched oxybutynin
WO2009035598A1 (en) 2007-09-10 2009-03-19 Concert Pharmaceuticals, Inc. Deuterated pirfenidone
US20090118238A1 (en) 2007-09-17 2009-05-07 Protia, Llc Deuterium-enriched alendronate
US20090082471A1 (en) 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched fingolimod
US20090088416A1 (en) 2007-09-26 2009-04-02 Protia, Llc Deuterium-enriched lapaquistat
JP2010540635A (ja) 2007-10-02 2010-12-24 コンサート ファーマシューティカルズ インコーポレイテッド ピリミジンジオン誘導体
US20090105338A1 (en) 2007-10-18 2009-04-23 Protia, Llc Deuterium-enriched gabexate mesylate
US8410124B2 (en) 2007-10-18 2013-04-02 Concert Pharmaceuticals Inc. Deuterated etravirine
CA2703591C (en) 2007-10-26 2013-05-07 Concert Pharmaceuticals, Inc. Deuterated darunavir
UA108193C2 (uk) * 2008-12-04 2015-04-10 Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
HUE027698T2 (en) * 2009-05-26 2016-10-28 Abbvie Bahamas Ltd Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
KR102516131B1 (ko) 2018-09-21 2023-04-03 삼성디스플레이 주식회사 표시 장치 및 그의 제조 방법

Also Published As

Publication number Publication date
CN102307872B (zh) 2016-06-15
CO6390038A2 (es) 2012-02-29
DOP2011000152A (es) 2011-10-31
PE20120119A1 (es) 2012-03-18
HK1162031A1 (zh) 2012-08-17
EP3666758A1 (en) 2020-06-17
JP6034412B2 (ja) 2016-11-30
IL212960A (en) 2016-09-29
ECSP11011174A (es) 2011-08-31
EP3101019A1 (en) 2016-12-07
PH12015502581A1 (en) 2018-11-12
EP2376480A2 (en) 2011-10-19
ZA201103806B (en) 2012-02-29
RU2621052C2 (ru) 2017-05-31
RU2013133800A (ru) 2015-01-27
NZ614305A (en) 2015-03-27
UY32305A (es) 2010-07-30
PH12015502581B1 (en) 2018-11-12
SMT201600313B (it) 2016-11-10
CA2744711A1 (en) 2010-06-10
WO2010065865A3 (en) 2010-09-16
AU2009322219B2 (en) 2013-05-09
KR20110103406A (ko) 2011-09-20
CR20160269A (es) 2016-08-16
SI2376480T1 (sl) 2016-10-28
PE20142316A1 (es) 2015-02-04
CA2744711C (en) 2017-06-27
KR20170007486A (ko) 2017-01-18
CL2011001313A1 (es) 2011-10-07
PT2376480T (pt) 2016-10-26
NZ592801A (en) 2013-08-30
IL212960A0 (en) 2011-07-31
CN106008322B (zh) 2018-09-04
ME02642B (me) 2017-06-20
AU2009322219A1 (en) 2010-06-10
CR20110351A (es) 2011-10-27
LT2376480T (lt) 2016-09-12
JP5684720B2 (ja) 2015-03-18
EP2376480B1 (en) 2016-06-01
CY1117929T1 (el) 2017-05-17
TWI600652B (zh) 2017-10-01
TW201029992A (en) 2010-08-16
HUE029289T2 (en) 2017-02-28
JP2015129134A (ja) 2015-07-16
TW201538482A (zh) 2015-10-16
MY158932A (en) 2016-11-30
TWI600642B (zh) 2017-10-01
AR074510A1 (es) 2011-01-19
RU2497822C2 (ru) 2013-11-10
CN106008322A (zh) 2016-10-12
JP2012511020A (ja) 2012-05-17
HRP20161085T1 (hr) 2016-10-21
KR101787993B1 (ko) 2017-10-19
BRPI0922771A2 (pt) 2018-11-06
WO2010065865A2 (en) 2010-06-10
UY32680A (es) 2011-02-28
CN102307872A (zh) 2012-01-04
MX2011005922A (es) 2011-06-16
PL2376480T3 (pl) 2016-12-30
SG10201500767RA (en) 2015-04-29
ES2588374T3 (es) 2016-11-02
IL245889B (en) 2018-05-31
IL245889A0 (en) 2016-07-31
RU2011127402A (ru) 2013-01-10
MX363470B (es) 2019-03-25
KR101692705B1 (ko) 2017-01-04
RS55176B1 (sr) 2017-01-31

Similar Documents

Publication Publication Date Title
DK2376480T3 (da) Sulfonamidderivater som bcl-2-selektive apoptoseinducerende midler til behandling af cancer og immunsygdomme
US9315488B2 (en) Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US9045420B2 (en) Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US9029404B2 (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2011068560A1 (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2010065824A2 (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
AU2013211540B2 (en) Sulfonamide derivatives as Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases